xml version 1.0 encoding UTF-8 standalone no
record xmlns http:www.loc.govMARC21slim xmlns:xsi http:www.w3.org2001XMLSchema-instance xsi:schemaLocation http:www.loc.govstandardsmarcxmlschemaMARC21slim.xsd
leader nam Ka
controlfield tag 001 001993684
007 cr mnu|||uuuuu
008 090326s2008 flu s 000 0 eng d
datafield ind1 8 ind2 024
subfield code a E14-SFE0002406
Natriuretic peptides as a humoral link between the heart and the gastrointestinal system
h [electronic resource] /
by Anteneh Addisu.
[Tampa, Fla] :
b University of South Florida,
Title from PDF of title page.
Document formatted into pages; contains 132 pages.
Dissertation (Ph.D.)--University of South Florida, 2008.
Includes bibliographical references.
Text (Electronic dissertation) in PDF format.
ABSTRACT: Natriuretic peptides are a family of hormones released by several different tissues and exert various physiological functions by coupling with cell surface receptors and increasing intracellular cyclic gyanylyl monophosphate (cGMP). Atrial Natriuretic Peptide (ANP) and B-type Natriuretic Peptide (BNP) are released in response to mechanical stretch of the atrial or ventricular myocardium, respectively and their plasma level is markedly elevated during myocardial infarction and heart failure. Heart failure in turn is associated with symptoms suggestive of perturbed gastrointestinal function such as nausea, indigestion and malabsorption. Intragastric pressure was monitored using a balloon catheter in anesthetized mice. The pressure before and after treatment with a 10 ng/g intravenous dose of ANP, BNP, CNP or vehicle was compared and analyzed. All the natriuretic peptides significantly decreased intragastric pressure compared to vehicle.These effects were attenuated or absent in natriuretic peptide receptor type-A (NPR-A) knockout mice. Furthermore, the effect of BNP on gastric emptying and intestinal absorption was examined using a meal consisting of fluorescence labeled dextran gavage fed to awake mice. BNP significantly decreased gastric emptying and absorption as compared to vehicle control. Using a cryoinfarction acute myocardial injury model, our investigation showed that mice with acute cryoinfarction had a significantly lower gastric emptying and absorption of a gavage fed meal compared to sham. Circulating BNP levels were significantly higher in the infarcted mice compared to controls. Immunostaining showed amplified distribution of the non-muscle myosin type-II (MCH-II) in BNP treated mice. MCH-II is involved in movement of intestinal villi. In summary, natriuretic peptides in general and BNP in particular, have gastrointestinal effects including reduced gastric contractility, emptying and absorption.In addition to their effect on smooth muscle relaxation mediated by cGMP, natriuretic peptides appear to have an effect on distribution of MHC-II in cells of the intestinal villi. We postulate that these effects are aimed at mediating a 'communication' between the cardiovascular and gastrointestinal systems. Further characterization of such a link will not only add a dimension to the understanding of the pathophysiology of heart failure but also enhances the search for further therapeutic targets.
Mode of access: World Wide Web.
System requirements: World Wide Web browser and PDF reader.
Co-advisor: John R. Dietz, Ph.D.
Co-advisor: William R. Gower. Jr., Ph.D.
t USF Electronic Theses and Dissertations.
Natriuretic Peptides As A Humoral Link Between The Heart And The Gastrointetsinal System by Anteneh Addisu A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Medicine Department of Molecular Pharmacology and Physiology College of Medicine University of South Florida Co-Major Professor: John R. Dietz, Ph.D. Co-Major Professor: William R. Gower. Jr., Ph.D. Kendall F. Morris, Ph.D. Stanley J. Nazian, Ph.D. Ravi Sankar, Ph.D. Date of Approval: March 18, 2008 Keywords: BNP, volume regulation, heart failure, interorgan communication, non-muscle myosins Copyright 2008 Anteneh Addisu
DEDICATION I dedicate this thesis to my loving family, my wife Sirgut Tirusew and my children Leeyu and Yonaas, my parents Addisu Merdassa and my mom Tsedale Sahlemariam. Your, de dication, sacrifices, prayers and love has made this possible and fo r that I am eternally thankful.
ACKNOWLEDGMENTS I owe a huge debt of gratitude to my mentor Dr. John R. Dietz. Your exemplary guidance has enriched my training in so many ways; but more importantly in encourag ing my keenness to become an independent researcher. Your unres erved commitment to my success will always be cherished. Thank you. My co-major professor, Dr. W illiam R. Gower Jr. has been most generous with his valuable time an d resources to assure my success, and I would like to take this opportunity to thank him. I thank my committee members, Drs. Kendall F. Morris, Stanley J. Nazian and Ravi Sankar for thei r support and encouragement. Each one of you has been very supportive whenever I needed your guidance or assistance. Thank you for everything. Our department Chair Dr. Bruce Lindsey had been a source of continued encouragement and resour ceful advice. It truly was an honor and privilege to have been a member of your department. A heart felt thanks also goes to Dr. Kersti K. Linask, she not only kindled my interest in non-muscle my osins, but also kindly hosted me in her lab where I learned the techniques of immuno staining. Without
her help the work on non-muscle myosins would not have been possible. Similarly, the electron microscopy images would not have been possible without the help of Dr Truitt Sutton; and I would like to express my thanks to him. I also owe a debt of gratitude to Carol Landon, who has held my hand during those early days of mo use surgery. Your superb surgical and technical skills will always insp ire me and I thank you very much for all you have done. I also thank Barbara Nicholson for her kindness and patience in addressing the s eemingly endless questions. Bridget and Joyce have always been most helpful in handling the numerous paper work that inevitably come up in the course of a graduate study. I would also like to thank the staff at the office of graduate and post doctoral affairs, Kathy Zahn, Susa n Chapman and Francjesca Jackson for their continued assistance throug h the myriad of formalities that arose at every juncture. Once again, I would like to acknowledge my immediate and extended family including my brot hers and sisters, uncles and aunts and grandparents who have kept my spirits up when at times I felt it may not be worth it. Thanks for all the support. I will always treasure your love and will forever be grateful.
i TABLE OF CONTENTS LIST OF TABLES iv LIST OF FIGURES v ABSTRACT viii CHAPTER ONE INTRODUCTION AND BACKGROUND Body Fluid Volume Sensing and Regulation 1 The Natriuretic Peptides 5 Natriuretic Peptide Receptors 11 Tissue Distribution of Natriureti c Peptides and their Receptors 15 Physiological Effects of the Natriuretic Peptides 15 Gastrointetsinal Effects of Natriuretic Peptides 17 CHAPTER TWO MATERIALS AND METHODS Measurement of Gastric Contract ility and Intragastric pressure 22 Experimental Animals 22 Surgical Preparation 23 Positive and Negative Controls 25 Blood Pressure Measurement 28 Measurement of Gastric Emptying 28 Measurement of Absorption 29 Induction of Myocardial I schemia (Myocardial Injury) 31
ii Plasma BNP measurement by Radioimmunoassay 32 Immunostaining for Non-Muscle Myosin 33 Statistical Methods 36 CHAPTER THREETHE EFFECT OF NATRIURETIC PPETIDES ON INTRAGASTRIC PRESSURE, GASTRI C EMPTYING AND ABSORPTION Introduction 37 Results 39 Discussion 56 CHAPTER FOUR THE ROLE OF BNP IN THE GASTROINTETSINAL MANIFESTAION OF MYOCARDIAL INJURY Introduction 62 Results 65 Discussion 72 CHAPTER FIVE BNP AND NON MUSCLE MYOSINS IN THE GASTROINTETSINAL TRACT Introduction 77 Results 85 Discussion 92 CHAPTER SIX SUMMARY AND CONCLUSIONS 98 PERSPECTIVE 100 REFERENCES CITED 102
iii BIBLIOGRAPHY 128 APPENDICES 129 Appendix A Abbreviations Used 130 ABOUT THE AUTHOR End Page
iv LIST OF TABLES Table 1 Composition of modified Krebss solution 26 Table 2 Molar concentration of modified Krebs solution 27 Table 3 Peptides used in this study 30
v LIST OF FIGURES Figure 1 Linear peptide structure of the natriuretic peptides 6 Figure 2 Schematic representation of the synthesis of natriuretic peptides ANP, BNP and CNP 8 Figure 3 Schematic representations of the natriuretic peptide receptors 12 Figure 4 A model for natriuretic peptide receptor activation 13 Figure 5 Typical pressure wave pattern of a basal gastric contraction 39 Figure 6 Simultaneous record ing of blood pressure and intragastric pressure 40 Figure 7 The effect of intravenous admi nistration of Gherelin on intragastric pressure 41 Figure 8 Three individual experiments showing intragastric pressure after a 10 ng /g iv bolus of ANP, BNP and CNP 42 Figure 9 Typical recoding of post peptide injection gastric contraction wave pattern 43 Figure 10 The effect of C-ANP 4-23 on gastric pressure 44 Figure 11 BNP did not change gastric pressure in NPR-A knock out mice 45
vi Figure 12 Determination of baseline and peak intragastric pressure before and after peptide injection 46 Figure 13 Mean reduction in intragastric pressure following intravenous BNP injection 48 Figure 14 Mean reduction in intragastric pressure following intr avenous ANP injection 49 Figure 15 Mean reduction in intragastric pressure following intravenous CNP injection 50 Figure 16 The Effect of BNP on gastric emptying 51 Figure 17 Dose dependent reduction of gastric emptying 52 Figure 18 The Effect of BNP on absorption 53 Figure 19 Comparison of plasma fluorescence following intravenous FITC-dextran injection; BNP vs. Vehicle 54 Figure 20 Representative histolog ical appearance of the myocardium 14 days after cryoinfarction 66 Figure 21 Comparison of percen t gastric emptying in Sham vs. MI wild Type mice, 1 week post MI 67 Figure 22 Comparison of percen t gastric emptying in Sham vs. MI Wild Type mice 68 Figure 23 Comparison of percen t gastric emptying in Sham vs. MI NPR-A knockout mice 69 Figure 24 Comparison of absorp tion measured in relative plasma fluorescence units. Sham vs. MI, WT mice 70 Figure 25 Comparison of abso rption measured in relative plasma fluorescence units. Sham vs. MI, NPR-A KO 71
vii Figure 26 Schematic diagram of non muscle myosin-II 78 Figure 27 Schematic depiction and electron micrograph of the structures of intestinal villi 79 Figure 28 Cytoskeletal structures in the intestinal microvillus 80 Figure 29 Ultra structures of the microvilli cytoskeleton 81 Figure 30 Transmission Electron micrographs of intest inal villi in various state of contraction 82 Figure 31 Schematic depiction of tight junctions 83 Figure 32 Toluidine blue stained 3m sections of a mouse intestinal tissues 85 Figure 33 Higher magnification view of jejunal villi 86 Figure 34 Electron micrograph s of the intestinal microvilli Co ntrol vs. BNP treated 87 Figure 35 Jejunal villi immunostained for non muscle myos in type IIB Control 88 Figure 36 Comparative images of control vs. BNP treated jejunal villi 89 Figure 37 Jejunal villi and smooth muscle bundles immunostai ned for non muscle myosin 90 Figure 38 A 3 m sections of a mouse jejunum immunostained for non muscle myosin type IIB. Control vs. BNP 91
viii NATRIURETIC PEPTIDES AS A HUMORAL LINK BETWEEN THE HEART AND THE GASTROINTETSINAL SYSTEM Anteneh Addisu ABSTRACT Natriuretic peptides are a family of hormones released by several different tissues and exert various physiological functions by coupling with cell surface receptors and increa sing intracellular cyclic gyanylyl monophosphate (cGMP). Atrial Natriuretic Peptide (ANP) and B-type Natriuretic Peptide (BNP) are released in response to mechanical stretch of the atrial or ventricula r myocardium, respectively and their plasma level is markedly elevated during myocardial infarction and heart failure. Heart failure in turn is associated with symptoms suggestive of perturbed gastrointest inal function such as nausea, indigestion and malabsorption. Intragastric pressure was monitored using a balloon catheter in anesthetized mice. The pressure befo re and after treatment with a 10 ng/g intravenous dose of ANP, BNP, CNP or vehicle was compared and analyzed. All the natriuretic peptides significantly decreased intragastric pressure compared to vehicle. These effects were
ix attenuated or absent in natriureti c peptide receptor type-A (NPR-A) knockout mice. Furthermore, the effect of BNP on gastric emptying and intestinal absorption was examined using a meal consisting of fluorescence labeled dextran ga vage fed to awake mice. BNP significantly decreased gastric empt ying and absorption as compared to vehicle control. Using a cryoin farction acute myocardial injury model, our investigation showed that mice with acute cryoinfarction had a significantly lower gastric empt ying and absorption of a gavage fed meal compared to sham. Circulating BNP levels were significantly higher in the infarcted mice comp ared to controls. Immunostaining showed amplified distribution of the non-muscle myosin type-II (MCHII) in BNP treated mice. MCH-II is in volved in movement of intestinal villi. In summary, natriuretic pept ides in general and BNP in particular, have gastrointestinal effects including reduced gastric contractility, emptying and absorption. In addition to their effect on smooth muscle relaxation mediated by cGMP, natriuretic peptides appear to have an effect on distribution of MHC-II in cells of the intestinal villi. We postulate that these effe cts are aimed at mediating a communication between the card iovascular and gastrointestinal systems. Further characterization of such a link will not only add a
x dimension to the understanding of th e pathophysiology of heart failure but also enhances the search fo r further therapeutic targets.
1 CHAPTER ONE INTRODUCTION AND BACKGROUND Since maintaining body fluid volu me is one of the most tightly regulated physiological function s, animals have evolved with increasingly sophisticated mechan isms for rapidly detecting and responding to changes in fluid volume In vertebrates, the vascular low pressure volume sensors are em bedded within the walls of the myocardium and large pulmonary bl ood vessels. These volume sensors detect changes in pressure (or vo lume) induced stretch of the vessel and myocardial wall. Signals from th ese receptors travel via afferent fibers of the vagus nerve to the solitary tract nucleus of the medulla oblongata in the brain stem (Donald & Shepherd, 1979; Thorn et al., 1976). Feedback activation or deactivation of neural signals back to the target organs then modulate me chanisms that result in more or less diuresis, natriuresis or vascula r tone depending on the bodys requirement. However even as early as the first half of the last century there were studies that suggested there may be humoral (non neuronal) system of receptors that responded to the change in
2 pressure or volume stretching th e atrial myocardium. For instance, expansion of plasma volume by blood transfusion to healthy dogs was shown to increase urine flow (Met calf, 1944). Similarly infusion of isooncotic solution of albumin was shown to produce marked diuresis in human volunteers (Welt & Orloff, 1951). Strauss et al reported that infusion of isotonic (0.9%) salin e to healthy volunteers increased water diuresis during recumbency ; and they noted that the body position influenced how the infused volume is distributed and sensed by the atrium (Strauss et al., 1951). Th e role of atrial stretch in such volume induced diuresis was already experimentally established in the mid 1950s (Henry & Pearce, 1956). Henry and colleagues used a balloon to distend the atrium in do gs and showed that urine output was increased corresponding to the de gree of atrial distension. In their paper entitled The possible role of cardiac atrial stretch receptors in the induction of changes in urine flow , Henry and Pearce noted that vagotomy did not abolish the diuretic response to isotonic infusions; and this led to their conclusion in 1956 that t he body may be provided with other receptors or pathways by which it receives information which makes possible the regulation of blood volume by the control of urine flow . Nevertheless, until only a littl e over two decades ago; the outcome of the activation of atrial and venous stretch receptors was
3 believed to almost entirely depend on the modulation of autonomic nerve activity or varying levels of secretion of antidiuretic hormone (ADH) from the neurohypohysis. In 1980 Adolfo de Bold reported his seminal discovery that intravenous injection of extract from the rat atrium produced a marked diuresis (de Bold et al., 1981). Thus it became apparent that the atrium produced a diuretic and natriuretic substance that was released into the circulation and worked through a receptor system that is di stinct from the neurally mediated feedback inhibition. This natriuretic substance was initially termed atrial natriuretic factor (ANF). Wi th this discovery, it also became apparent that the heart has an endocrine function and directly communicates with the kidney by virtue of its own cardiac hormone systems. The presence of granular structur es in the atrial myocytes of several different species was one of the earliest findings of the advent of electron microscopy (Jamieson & Palade, 1964; Kisch, 1956; Palade, 1961). Moreover, the possible relationsh ip between atrial granules and the degree of sensitivity of the atri um to volume or salt loading was suggested as early as 1976 (Marie et al., 1976). However it was with de Bolds seminal experiments that the content of these atrial granules was clearly hinted to be a potent natriuretic substance that directly
4 influenced renal handling of salt and water (de Bold et al., 1981; de Bold., 1985). The atrial natriuretic fact or was later determined to be a peptide produced by the atrial myoc ardium (Currie et al., 1984; Flynn TG, 1983; Misono et al., 1984) and it is currently more commonly referred to as Atrial Natriureti c Peptide (ANP). The ANP gene was subsequently sequenced revealing the remarkable similarity and genetic conservation of the natriure tic peptides across many species (Seidman et al., 1984).
5 The Natriuretic Peptides The identification of ANP in 1985 was soon followed by the discovery of a similar peptide in po rcine brain (Sudoh et al., 1988) hence termed as brain natriuretic peptide (BNP). However it was later discovered that BNP was another cardiac hormone and is actually absent in brains of some species (Ogawa et al., 1991; Ogawa et al., 1990). In 1990, C-type natriuretic pept ide (CNP) was isolated from the brain of pigs, bullfrogs and two species of teleost fishes (Sudoh et al., 1990; Suzuki et al., 1991; Yosh ihara et al., 1990). The three natriuretic peptides share a common structural feature, a conserved 17 amino acid ring with variable Nand C-terminal sequences (figure 1). The number of amino acid residu es extending from the C terminal is usually 5 for ANP, 6 for BNP an d 0 for CNP with few exceptions. Thus the C-terminal sequence appears to be a major determinant of biological activity of the natriuretic peptides. CNP is the most conserved of the three peptides ac ross species and it is believed to have evolved earlier in the phylogenetic tree, ANP and BNP being derived from it at a later point in evolution. In rece nt years a fourth natriuretic peptide, a 38 amino ac id peptide known as deandropsis natriuretic peptide (DNP) has been isolated from the venom of the green mamba snake (Munagala et al., 2004). Immunoreactivity to DNP has been shown in human and rodent plasma (Johns et al., 2007;
Schirger et al., 1999). However, a gene coding for it has not yet been isolated and the physiological significance of DNP in humans (if any) remains poorly understood. Figure 1. Linear peptide structure of the natriuretic peptides Adapted from (Cea, 2005) In humans, the ANP and BNP genes are localized in tandem on chromosome 1. Transcription of the ANP gene yields an mRNA that encodes a 151 amino acid metabolic precursor known as preproANP. 6
7 PreproANP is rapidly converted to a 126 amino acid peptide proANP. ProANP is the predominant storag e form of ANP and the major constituent of atrial granules. Atrial distension is the major signal for the release of ANP (Anderson et al ., 1986; Dietz, 1984; Dietz et al., 1991; Kinnunen et al., 1992; Sato et al., 1986). When such a signal is sensed; proANP is cleaved by a cardiac serine protease (corin) into an amino fragment pro-ANP (amino acids 1-98) and ANP, the biologically active fragment (amino acids 99-126) (Bloch et al., 1986; Vuolteenaho et al., 1985). Further cleavage of proANP (1-98) results in more peptide fragments (1-30) and (31-67); these fragments also have biological activity and neutraliz ation of proANP 1-30 was shown to exacerbate hypertension in spontaneously hypertensive rats (Dietz et al., 2001; Dietz et al., 2003; Dietz et al., 1995; Dietz & Villarreal, 1995; Vesely et al., 1999). The amin o acid sequences of the main biologically active hormone ANP 99-126 are identical in all mammalian species except at residue 110, which is methionine in humans (Kangawa et al., 1984; Lewicki et al., 1986; Vlasuk et al., 1986) but isoleucine in rats, mice and rabbits (Oikawa et al., 1985; Seidman et al., 1984; Yamanaka et al., 1984). Alternate processing of the prepro ANP in the kidney produces a 32 amino acid peptide known as urodilatin. Urodilatin is secreted in to the lumen of the distal nephron (medullary collecting duct) where it is believed to be involved in
regulation of sodium and water absorption in the kidney (Forssmann et al., 1998; Kuhn, 2005). Physiologically plasma ANP is markedly increased in response to pressure or volume overload or in pathological states such as heart failure or ventricular hypertrophy. However the plasma half life is rather short, averaging less than 3 minutes which indicates that the release of ANP serves to counteract the effect of acute pressure or volume overload (Lang et al., 1985; Ruskoaho, 1992). Figure 2. Synthesis of natriuretic peptides and prohormones Adapted from Koller and Goeddel 1992 8
9 Human BNP is produced as a 132 amino acid residue preproBNP that is subsequently cleaved to a 108 amino acid prohormone. Additional cleavage yields the 32 amino acid active hormone and an inactive 76 amino acid amino term inal (NT) fragment sometimes known as NT-proBNP (Saito et al ., 1989; Seilhamer et al., 1989; Sudoh et al., 1988). Ventricular BNP is not stored in granules in the myocytes, instead BNP production is regulated at the transcription level by various stimuli, the main st imulus for BNP synthesis is stretch of the ventricular wall by volume and/or pressure overload (Grpin et al., 1994; Thuerauf et al., 1994). Even though the BNP gene is located in tandem with the ANP gene; BNP expression doesnt always parallel ANP gene expression. The response of the BNP gene is quicker than that of ANP suggesting a more acut e and sustained role for BNP in response to a volume overload. In crease in BNP mRNA is detected within one hour of increased ventricular wall tension induced by increased venous volume or acute my ocardial infarction (Hama et al., 1995; Nakagawa et al., 1995). BNP ha s a much longer half-life (than ANP) of about 20 minutes (Espiner et al., 1995) and with sustained cardiac stress; as in the case of heart failure, BNP mRNA levels have been shown to remain increased (Tokola et al., 2001). BNP secretion takes two forms, constitutive, where the BNP is secreted as fast as it is being formed and a regulated pathway where the BNP is stored in
10 granules prior to being secreted (Kelly, 1985). Ventricular myocytes shift between the two pathways depending on the stimulus, the constitutive secretion be ing called upon when there is acute need for BNP secretion and the regulated path ways operating when there is a sustained myocardial stress such as chronic heart failure (Bloch et al., 1986; Kelly, 1985). CNP is mainly expressed in the brain, chondrocytes and endothelial tissue. Myocardial tissue has a much smaller amount of CNP than ANP or BNP and CNP is no t stored in granules (Yandle, 1994). In humans, proCNP contains 103 amino acid residues and it is cleaved to a 53 amino acid CNP in the brain, the heart and endothelial tissue. Further cleavage yields a 22 amino acid peptide which is the predominantly circulating form of CNP (Stingo et al., 1992; Totsune et al., 1994; Wu et al., 2003). Whil e CNP 53 is believed to be predominantly a neurotransmitter, it is also involved in bone and cartilage growth; CNP 22 is mainly in volved in autocrine and paracrine regulation of vascular tone (D'Souza et al., 2004). CNP has less effect on diuresis and natriuresis than A NP or BNP and a more potent effect on smooth muscle relaxation, it is th us believed to be mainly involved in the regulation of coronary vascular tone in the heart (Clavell et al., 1993; Komatsu et al., 1992; Sudoh et al., 1990).
11 Natriuretic Peptide Receptors The natriuretic peptide rece ptors are members of the transmembrane guanylyl cyclase family of enzymes that are widely distributed in human and animal ti ssues. There are at least seven different guanylyl cyclase enzymes id entified so far (Anand-Srivastava & Trachte, 1993; Garbers et al., 2006). Natriuretic peptide receptor (NPR) types A and B (NPR-A and NPR-B) are structurally similar and exist as homodimers or homotetr amers in intact mammalian cells (Chinkers & Wilson, 1992; Iwata et al., 1991; Katafuchi et al., 1994). The receptor consists of an extr a cellular ligand-binding domain, a membrane spanning domain and intr acellular kinase-like and guanylyl cyclase domains (Nagase et al., 1997; Potter, 2005). Both ANP and BNP bind to NPR-A although ANP is known to bind with at least 10 times more affinity to NPR-A (Kambayashi et al., 1990; Nakao et al., 1991). NPR-B has similar structure to NPR-A, but selectively binds to CNP. Natriuretic peptide recept or type-C (NPR-C) has a short intracellular sequence that doesnt have a guanylyl cyclase domain.
Figure 3. Schematic representation of the natriuretic peptide receptors Adapted from Potter et al., 2006 Ligand binding to the receptor leads to the activation of the guanylyl cyclase and results in a conformational change. The C-terminal guanylyl cyclase then comes into a tight association that leads to conversion of guanosine triphospate (GTP) to 3cyclic guanosine monophosphate (cGMP) (Chinkers & Wilson, 1992; Foster et al., 1999). The ATP binding site in the kinase homology domain (KHD) is believed to be essential for ligand-induced signal transduction and 12
deletion of the KHD depresses the guanylyl cyclase catalytic region (Chinkers & Garbers, 1989). Phosphorylation of amino acid residues in the KHD of the receptor is essential for normal function and dephosphorylation appears to be one method of the natriuretic peptide receptor desensitization (Potter & Garbers, 1992; Potter & Hunter, 1998). Figure. 4. A model for natriuretic peptide receptor activation Adapted from Silberbach and Roberts 2001 13
14 The end result of these mechanis ms of receptor activation is increased concentration of intracellu lar cGMP; cGMP in turn exerts its physiological effects by binding to one of three cGMP binding proteins. cGMP dependent protein kinases (PKG), cGMP binding phosphodiesterases (PDE) and cyc lic nucleotide gated ion channels (Pfeifer et al., 1996; Rybalkin et al., 2003; Smolenski et al., 1998). As mentioned earlier, natriuretic peptide receptor type-C (NPRC) has a short intracellular sequen ce that doesnt have a guanylyl cyclase domain. The major role of NPR -C was initially believed to be as a clearance receptor and regulation of the plasma concentration of ANP and BNP through receptor mediated internalization and degradation (Matsukawa et al., 1999). However recent evidence suggests that NPR-C is involved in signaling that leads to reduction of adenylyl cyclase activity through activation of inhibitory G protein (Gi) (AnandSrivastava & Trachte, 1993; Rose & Giles, 2007). The natriuretic peptides are cleared from the circulation by three mechanisms. Endocystosis and degr adation by coupling with NPR-C, enzymatic cleavage by neutral endopetidases and by glomerular filtration and excretion in the urin e (Boerrigter & Burnett, 2004; Freda & Francis, 2006).
15 Tissue Distribution of Natriureti c Peptides and their Receptors The atrial and ventricular cardio myocytes are the main sites of production and storage of ANP and BNP, respectively. This was confirmed through seminal experiments that showed that atrial appendectomy resulted in marked redu ction of both the plasma levels of ANP and the diuretic and natriure tic effect seen in response to a volume load with isotonic sa line (Veress & Sonnenberg, 1984; Villarreal et al., 1986). Nevertheless, ANP and BNP mRNA have been detected in several non-cardiac tissues including the adrenal glands, the kidneys, lung, the gonads, lymp hoid tissue and the gut (Gerbes et al., 1994; Gower et al., 1994; Gowe r et al., 2003; Li et al., 2006; Nguyen et al., 1990; Sharkey et al., 1991; Vollmar, 1990). Natriuretic peptide receptors have also been dete cted in the gastrointestinal (GI) tract of both non-mammalian and mammalian species including humans (Gower & Skvorak, 1997; Li & Goy, 1993; Lowe et al., 1989; Ohyama et al., 1992; Schulz et al., 1998). Physiological Effects of the Natriuretic Peptides Vascular relaxation is one of the most important physiological actions of the natriuretic peptides. Binding of cGMP to PKG is known to regulate ion channels in vascular smooth muscle cells with a cascade of molecular events that culmin ate in a lower concentration of
16 intracellular calcium. These effects include reduction of calcium influx, increase of calcium efflux and prom otion of calcium sequestration in sarcoplasmic reticulum (Tamaoki et al., 1997). Reduced vascular tone and vasodilatation in turn results in lower total peripheral vascular resistance which has important physiological benefit on the cardiovascular system; especially in the face of cardiac ischemia or volume overload. Such vascular relaxa tion and vasodilatation will also result in reduced pressure in the renal afferent arterioles thereby increasing glomerular filtration, prom oting diuresis and natriuresis. In addition to these effects on vascu lar smooth muscle cells, the direct effect of ANP and BNP on renal tubules and mesangial cells as well as inhibition of the renin angiotensin aldosterone (RAAS) system results in decreased sodium absorption from the renal tubules (Lohmeier et al., 1995; Zeidel, 1993). ANP and BNP are also known to decrease sympathetic outflow and catecholamine release from peri pheral sympathetic neurons which benefits the cardiovascular system since it leads to lower blood pressure, decreased heart rate an d natriuresis (Levin et al., 1988). Further support for the importance of the natriuretic peptides in blood pressure and blood volume regulati on comes from data showing that NPR-A transgenic mice show chro nic hypertension and ventricular hypertrophy (John et al., 1995). NPR-A transgenic mice were recently
17 shown to have an upregulation of the angiotensin converting enzyme (ACE) and angiotensin II type 1a rece ptor (AT1) mRNA by up to fourfold signifying the importance of the natriuretic peptides in counteracting the effect of the re nin angiotensin aldosterone (RAS) system (Vellaichamy et al., 2007). It is also shown that NPR-A knockout mice exhibit dysregulation of matrix metalloproteinases and tissue inhibitors of metalloprote inases; enzymes involved in the regulation of collagen synthesis and organization of myocardial fibrils (Li et al., 2000; Spinale, 2002). As a result NPR-A knockout mice show increased tendency towards myocar dial fibrosis, hypertrophy and eventually heart failure that leads to premature death as compared to the wild type mice. Gastrointestinal Effects of Natriuretic Peptides Natriuretic peptides are known to have several effects on contractile and absorptive function s in the GI tract. ANP has been shown to inhibit intestinal sodium and water absorption in teleost and mammalian intestines (Barros et al., 1990; Matsushita et al., 1991; O'Grady et al., 1985). A decrease in jejunal water absorption in response to intravascular volume overload was also shown in rats. Such a decrease in transjejunal wate r absorption was absent in rats that underwent right atrial append ectomy and this effect returned
18 when ANP was exogenously admini stered (Pettersson & Johnsson, 1989). Intravenous administration of BNP and CNP has also been shown to decrease jejunal electrolyte and water absorption in dogs (Morita et al., 1992). Earlier invest igations have also shown that injection of either ANP or BNP into th e cerebral ventricles inhibits thirst induced by water deprivation or an giotensin (Antunes-Rodrigues et al., 1985; Itoh et al., 1988; Zhu & Herb ert, 1996). Furthermore, ANP and BNP have been shown to have an indirect effect on uptake and excretion of sodium and water through inhibition of vasopressin and aldoseterone secretion (Janusze wicz et al., 1986; Nguyen et al., 1989). The effect of natriuretic peptides on contractility of GI smooth muscle has been documented beginn ing with the early discovery of these peptides and their receptors in the GI tract (Scott & Maric, 1991). Subsequent studies have confir med these findings showing that ANP, BNP and CNP all inhibit cont ractility of isolated gastric and intestinal smooth muscle cells fr om different species including humans(GuoCui et al., 2003; GuoJin et al., 2003; Yasuda et al., 2000). Apart from the traditional cardiac natriuretic peptides ANP, BNP, and CNP; the GI tract is also known to be a so urce of two peptides with structures very similar to the natriuretic peptides. Guanylin and
19 uroguanylin were first isolated fr om rat intestine and opossum urine and later found to be widely distributed in non-mammalian and mammalian species including humans (Beltowski, 2001; Date et al., 1998). In humans, uroguanylin is mainly expressed in the enterochromaaffin (EC) cells of the duodenum (where ANP is also expressed), whereas guanylin is expressed in the jejunum and the colon (Beltowski, 2001; Li et al., 2006). Uroguanylin is secreted in response to oral salt load and th e circulating hormone is known to mediate sodium balance in the post-prandial state by increasing renal excretion of sodium and potassium while the luminally secreted hormone leads to increased chloride and bicarbonate secretion in to the lumen of the intestine (Beltowski, 2001; Forte et al., 1996). Uroguanylin and guanylin mRNA ar e detectable in the atrial and ventricular myocardium and interestin gly, plasma levels of guanylin and uroguanylin are increased during heart failure and renal failure (Beltowski, 2001; Forte et al., 1996). Both guanylin and uroguanylin receptors are membrane bound guanylyl cyclase enzymes and activation of these receptors lead s to increased intracellular cGMP (Carrithers et al., 1999; Forte et al., 1996; Forte et al., 1999). Both synergistic and antagonistic intera ction between ANP and BNP on one hand and uroguanylin and guanylin on the other have been shown and there has been some suggestion that this evidence points to a
20 probable regulatory link between the kidney and the GI tract in the process of sodium and water balance (Santos-Neto et al., 2006). Taken together, the remarkable genetic conservation of the natriuretic peptides, the stimuli for their release and their effect on sodium and water uptake is strong evidence that they serve crucial physiological functions that conferred survival benefit earlier in evolutionary times and have since evolved to be important conveyers of signals among the various organ sy stems involved in cardiovascular homeostasis. While the cardio-renal link is no w sufficiently well established, there have been very few studies co nducted to assess the functional significance of the effect of natriu retic peptides on the GI tract and how this all fits in the bigger scheme of volume regulation. The early observations on the effect of natriu retic peptides as well as recent evidence showing the presence and role of a possible intestinal natriuretic peptide system raise several intriguing questions. If the heart sends humoral signals to th e kidney to decrease sodium absorption, shouldnt it also use the same signals to limit sodium and water absorption from the GI trac t? GI symptoms such as nausea, indigestion and malabsorption are freque nt clinical findings in the face of acute heart attack or chronic he art failure, states where BNP levels are elevated. Could BNP be responsi ble for some of these symptoms?
21 If so, could there be potential target s of therapy for heart failure in the GI tract? Our studies will provide evidence that the effect of natriuretic peptides on gastric and intestinal smooth muscle cell contractility has a functional dimension. By directly testing the effect of ANP, BNP and CNP on gastric contractility, gastric emptying and absorption we show that these peptides do decrease gastric emptying and absorption. Moreover BNP, a peptide with increasing clinical utility, is shown here to cause decreased gastric emptying and intestinal absorption following acute myocardial injury us ing a whole animal cryo induced acute MI model. While our data suggests that these effects may be mediated by NPR-A, we also show data that suggests a more direct effect on absorptive structures at the level of intestinal microvilli. Further characterization of the sign als involved in these functions not only adds a new dimension to card iovascular research but could also lead to identification of new ther apeutic targets for the treatment of heart failure.
22 CHAPTER TWO MATERIALS AND METHODS Measurement of Gastric Contracti lity and Intragastric Pressure These protocols were approved by the University of South Florida Institutional Animal Care and Use Committee. Experimental Animals NPR-A Knockout (KO) mice were obtained from our resident colony that was founded with path ogen-free breeding pairs and were genetically monitored by PCR of tailsnip DNA. The generation of NPRA knockout mice has previously been described in detail (Lopez et al., 1995). Wild type (C57BL/6) mice were purchased from commercial sources. The wild type (WT) mice were all males with ages ranging from 8 to 12 weeks and weight rang ing from 18-26 grams at the time of the experiment. The NPR-A KO mice ranged from 10 to 32 weeks in age and 24-38 grams in weight at the time of the experiment, with equal number of male and female KO mice in the experiment and vehicle group. The parental strain of the knockout mice was C57BL/6.
23 Surgical Preparation In order to objectively determ ine the effect of natriuretic peptides on gastric contractility, a method of measuring intragastric pressure before and after peptide in jection was developed as follows. The mice were anesthetized with so dium pentobarbital (0.9 mg/10 gm body weight) given intraperitoneally (ip) and supplemental doses of 0.5 mg given ip as needed. The mice were then placed on a temperature controlled surgical table and a tracheotomy was performed using a 20 ga. Luer-stub adapter. The right jugular vein was catheterized with polyethylene (PE)10 tubing for injections and infusions and the right carotid was catheterized with a 5 cm piece of PE tubing (o.d. 0.012, i.d. 0.006: Braintree Scientific, Inc.) attached to a 12-18 segment of PE 50 tubi ng for arterial blood pressure measurements. A 10 mm left sub-costal skin incision was made to access the stomach. A 3 mm vertical incision of the stomach fundus was made with cautery carefully choos ing a site that has minimal or no visible blood vessels. A 2-3 mm latex balloon fitted with PE tubing and primed with saline was inserted into the stomach. The balloon was then minimally distended by adding 20-25 l of saline and attached to a standard pressure transduc er (Gould/Statham DB25). The intragastric catheter was held in pl ace by the minimal distension of the balloon and suturing the stomach in cision was not necessary. The skin
24 incision was closed with 1-2 interru pted surgical sutures. Following these surgical preparations, the mice received a 100 l bolus of 0.9% saline intravenously (iv) via the ju gular catheter and then allowed a one hour equilibration period while being infused with 0.9 % saline iv at 5 l/minute. The saline bolus and infusion were administered to compensate for blood loss associated with the surgic al procedure and maintenance fluid requirement. Arteri al blood pressure, heart rate and intragastric pressure were monitore d continuously via the carotid and intragastric catheters and recorded on a data acquisition system (DATAQ Instruments, Akron, OH). The change in intragastric pr essure was measured as the difference between the peak and baseline pressure. The measurements were taken for thre e 30 minute periods. The basal gastric pressure was measured from 30 to 0 minutes before injection. Post injection period was from 10 to 40 minutes after injection to correspond with the peak plasma level of the peptides and the recovery period was from 90 to 120 minutes after injection corresponding to the period later th an 5 peptide half-lives (12). The changes in intragastric pressure duri ng each of the three periods were averaged for each mouse and the diffe rences in intragastric pressure between the experimental and vehicl e groups during the three periods were compared using a one way ANOVA with Fishers least significant
25 difference test (LSD) used as a post hoc test. A p value of <0.05 was considered the criteria for statistical significance. Positive and Negative Controls Gherelin, a hormone with known prokinetic gastrointestinal effect in rodents, was used as a positive control to ascertain that the waves of contraction we observed and recorded were indeed changes in gastric motility (Depoortere et al., 2005). Gherelin (Rat, Phoenix pharmaceuticals, C# 031-31, Lot # 423341) was administered at a dose of 50 g/kg body weight in 100 l of vehicle iv, a dose previously established to increase gastric motility in rodents. The vehicle was used as a negative control. The vehicle consisted of modified Krebs-Hensledt bicarbonate buffer equilibrated final PH = 7.4, dissolved in the order shown in table 1.
26 Table 1. Composition of modi fied Krebs solution (g/l) CaCl 2 0.220g MgSO 4 0.144g KCl 0.224g KH 2 PO 4 0.163g NaCl 6.72g NaHCO 3 2.1g Glucose 1g Albumin 1g
27 Table 2. Millimolar concentration of modified Krebs solution Na+ 140 K+ 4.2 Ca 2+ 1.5 Cl 123 Mg 2+ 1.2 HCO 3 25 H 2 PO 4 1.2 SO 4 1.2 Glucose 2.5 Albumin (BSA fraction V) 0.1%
28 Blood Pressure Measurement Mean arterial pressure was co ntinuously monitored using an intra-carotid catheter and record ed. Average blood pressure was measured for the same three peri ods as for the gastric pressure measurement. Pre vs. post peptid e injection blood pressures were compared to ascertain that our findings were not confounded by differences in blood pressure. Measurement of Gastric Emptying Conscious WT and NPR-A KO mice (n = 5 in each group) were given BNP at dose of 10 ng/g throug h the tail vein dissolved in 100 l of vehicle (modified Krebs solution) or the vehicle alone and immediately gavaged with 0.1 ml of 0.5 Mmol 70 kDa fluoresceinisothiocyanate (FITC)-dextran. The 70 kDa FITC-dextran is known to be non-diffusible across intestin al membrane thus suitable for measurement of emptying (Thorba ll, 1981). Thirty minutes after the gavage meal, the animals were euthanized and the stomach was separated and the intestine divided into 8 equal segments, each flushed with 3 ml of PBS and cent rifuged for 10 minutes. Fluorescence of the supernatant fluid was measured and the percent gastric emptying rate was compared in BN P treated vs. control for both WT and NPR-A KO mice. This method of evaluating gastric emptying has been previously established (Aube et al., 2006).
29 Measurement of Absorption Conscious WT & NPR-A KO mice (n = 5 in each group) were given 10 ng/g of BNP through the tail vein dissolved in 100 l of vehicle (modified Krebs solution) or the vehicle alone. The mice were then gavaged with 0.01 ml/g of a solution containing 22 mg/ml of 4 kDa FITC-dextran. Blood was collected via cardiac puncture under pentobarbital anesthesia. Fluorescence was quantified using relative fluorescence units in the plasma. Th e plasma fluorescence measured 1 hour after gavage feeding in WT an d NPR-A KO mice was compared for BNP treated vs. control. Similar comparisons were made for the subsequent experiments between sham vs. Mi in both WT and NPR-A KO mice. The group differences were analyzed using a t-test with p<0.05 considered the significant leve l for statistical difference. This method of evaluating gastric ab sorption has been previously established (Aube et al., 2006). We also compared the fluoresce nce of a 50 l plasma sample taken 1 hour after iv administration of 100 l of 0.5 mmol 4kDa FITCdextran in BNP treated vs. vehicle WT mice. The purpose of this test was to rule out the possibility that the changes in plasma fluorescence were produced by other actions of BNP such as increased excretion, redistribution or metabolism of the dextran as this effect of BNP has been previously established (Huxley et al., 1987).
30 The concentration of fluoresce in was determined using a fluorimeter (FLUOstar Galaxy, BMG La btechnologies) with an excitation wavelength at 485 nm and an emi ssion wavelength of 520 nm using serially diluted samples of the marker as standard. Table 3. Peptides used in this study ANP Rat ANP, Sigma, P # A8208 BNP Rat BNP-32, Phoenix Pharmaceuticals, 011-14, Lot # 421752 CNP Rat 32-53, Bachem, P # H-1296, Lot # B00656 c-ANF 4-23 Rat, Phoenix Pharmaceuticals Gherelin Rat, Phoenix Pharmace uticals, C # 031-31, Lot # 423341 In the initial experiments, the peptides were administered intravenously at 10 ng/g body weight This dose was chosen to raise and sustain the plasma levels ab ove 500 pg/ml; a level that is consistent with a greater than 90% lik elihood of heart failure (for BNP) in humans (Maisel & Mehra, 2005). For subsequent dose response experiments we administered BNP at 1, 5, 10 and 100 ng/g body weight iv.
31 Induction of Myocardial Ischemia (Myocardial Injury) Wild-type and NPR-A knockout mi ce were anesthetized with 23% isoflurane-oxygen flow at 500 ml/minute. A 2 mm incision was made through the skin, just distal to the 4th and 5th intercostal space. Blunt dissection through all thorac ic musculature, using a fine-tipped instrument was performed to a ccommodate passage of a probe induction catheter (PIC). Using digi tal pressure, the distal tip of the PIC (catheter cap in place) was flatte ned as much as possible (to aid in atraumatic insertion), and the PIC was then passed through the muscle wall. Prior to removing th e cap, the operator pinched the proximal tip of the PIC shut (to aid in the prevention of pneumothorax). The oxygen flow wa s then turned up to 2 L/min. The liquid-nitrogen-cooled probe was then quickly threaded through the PIC, to the full length of the PIC. If needed, the PIC was then gently repositioned so the bevel and the cooled probe were in direct contact with the left ventricle of the heart. Correct placement of the probe, with subsequent cardiac thermal in jury, was confirmed as the super cooled probe "grabbed" the warmer tissue of the heart, and remained affixed until the probe had warmed en ough for release. After passive release, the probe and PIC, as on e unit, were quickly withdrawn and the ribs were then immediately brou ght into apposition. A pre-loaded 1/2 cc syringe of tissue glue (VetBond ) was then used for closure.
32 The experiment to study emptying an d absorption were performed at 1 and 2 weeks after this surgical pr ocedure (cryo induced myocardial injury/infarction). Plasma BNP Measurement by Radioimmunoassay Plasma BNP levels were measured by radioimmunoassay (RIA). (Peninsula Laboratories, 5-2104 RI AS 9085). The assay is based upon the competition of 125 I-labeled peptide and unlabeled peptide (unknown sample) binding to the limited quantity of antibodies specific for peptide in each reaction mixture. As the quantity of peptide in the unknown sample in the reaction increases, the amount of 125 I-bound peptide able to bind to the antibo dy is decreased. By measuring the amount of 125 Ibound peptide as a function of the concentration of the peptide in standard reaction mixtures, a standard curve is constructed from which the concentr ation of peptide in the unknown sample can be determined. The summary of the assay protocol is as follows: 1A 100 l of unknown sample is pipetted in to duplicates glass test tubes 2100 l primary antibody is added to unknown samples, vortexed, and incubated overnight at 4C.
33 3100 l of the I 125 labeled peptide is added and incubated overnight at 4C. 4Goat rabbit antiserum and normal rabbit serum is added and vortexed at 4C an d incubated for 90 minutes 5500 l of RIA buffer is added, vortexed and centrifuged at 1700 x g for 20 minutes 6-The supernatant is aspirated o ff except in the total counts tube 7Use gamma counter to count the level of radioactivity 8The data obtained from the gamma counter is analyzed using the program Assayzap, Biosoft, GB, United Kingdom. The detailed assay protocol is found in the product insert for the assay kit (Phoenix pharmaceuticals, C# RK-011-17) The kit we used has a cross reac tivity of 41% with the mouse BNP and total binding of 46%; calc ulations were made accordingly. The detection range for this kit was 10-128 pg/ml. Immunostaining for Non-Muscle Myosins Two WT mice were given a bolus of BNP at 10 ng/g body weight in 100 l of modified Krebs solution followed by infusion of BNP at 1 ng/g for 30 minutes. One WT mouse was given 100 l of vehicle and given an infusion of vehicle for 30 minutes
34 1The animals were then euthanized and intestinal tissue collected and sectioned into duodenum jejunum, ileum and colon following anatomical demarcations. 2The tissue is fixed in 4% paraformaldehyde over-night at 4C. 3The next morning the tissue is washed with phosphate buffered saline (PBS) for 15 minutes twic e at room temperature with gentle rocking. 4After the wash, the tissue is dehydrated and permeabilized as follows. Tissue is placed in ascending concentration of 30, 50 and 70 % methanol each for 15 minutes. Then the tissue is placed in a solution composed of 100 % methanol: DMSO: 30% H 2 O 2 made at a ratio of 4:1:1. The tissue is left in this solution overnight at 4C 5The next morning the tissue is washed in 70 % methanol for 30 minutes at room temperature with rocking. 6Rehydration is accomplished by se rially placing the tissue in 70 % methanol/PBS for 30 minutes with rocking, then 50 % of methanol/PBS with rocking, then 1 ml of PBS for 30 minutes with rocking, 1 ml of PBSMT (PBS, milk, Tween 20) 30 minutes with rocking twice. 7The tissue is then incubated overnight with 1 ml of primary antibody diluted in PBSMT (1:250) with rocking at 4 C.
35 8The next morning the tissue is rinsed with PBSMT 2x with 1 ml for 1 hour at 4C, 4 x in 1 ml for 1 hour each at room temperature. 9Next the tissue is incubated overnight with 1 ml of the Secondary antibody diluted in PBSMT (1:250) at 4C while rocking. 10Next morning the tissue is wa shed as above with PBSMT 11Next tissue is rinsed with PBT (PBS and Tween -20 equal concentration). 12Post fixing in 4 % paraformaldehyde in PBS at 4 C overnight. 13Dehydration in the following sequen ce, 1 ml of PBT quick rinse, 1 ml PBT for 30 minutes at r oom temperature, 1 ml 50 % methanol for 30 minutes, 1 ml of 70 % methanol for 30 minutes at room temperature; 1 ml of 100 % methanol 30 minutes at room temperature twice. 14Plastic embedding is achieved by transferring the tissue from 100 % methanol to araldite em bedding medium and kept in medium for 3 hours. The tissue is then transferred into a fresh embedding medium into a mold on araldite rafts and the mold is kept overnight in 60 C oven to allow the araldite to harden.
36 15The hardened plastic embedded tissue is then trimmed and sectioned using a microtome at 13 m thickness. The sections pass automatically into water, th e sections are transferred onto a slide and allowed to dry for 510 minutes on the surface of a hot plate. The first and last sect ion are placed on one side and stained with toluidine blue to guide orientation. Details of the above technique ar e found in (Linask & Tsuda, 2000). Statistical Methods We used a one way analysis of variance (ANOVA) to compare the average intragastric pressure at baseline, immediately after and later than five peptide half-lives after peptide injections. Fishers least significant difference (LSD) test is used as a post hoc test. Two sample t-tests were used to compare the measures of gastric emptying and absorption between peptide treated vs. vehicle treated mice. Specifically percent gastric emptying between treated vs. vehicle and average relative fluorescence units between the peptide treated vs. vehicle groups were tested using a two sample t-test.
37 CHAPTER THREE THE EFFECT OF NATRIURETIC PEPTIDES ON INTRAGASTRIC PRESSURE, GASTRIC EMPT YING AND ABSOPRTION INTRODUCTION Measurement of gastric pressure using an intragastric balloon (manometry) offers the most direct way to quantify pressure changes inside the stomach (Malagelada & Stanghellini, 1985; Mearin & Malagelada, 1993). Other factors being constant, the measured gastric pressure is directly proportional to the force of contraction of the stomach wall (Mearin & Malagelada, 1993); therefore quantifying and comparing the rate of change in pressure between experimental groups yields a reliable and objective measure of gastric contractility. However, due to the inherent vari ability of baseline pressure among different animals, we further standardized the measurement by using the difference between the baseline an d peak of the gastric contraction wave in our analysis. This makes our measurement less prone to variability and a more objective way to compare differences in
38 pressure between or among differe nt groups of animals in these experiments. Our measurements of gastric em ptying and absorption were designed to be as close to the phys iological state as possible. We used gavage feeding of fluorescence labe led dextran and let the mice roam freely for 30 minutes, following whic h the surgery was performed and measurement taken. The 70 kDa FI TC-dextran was shown to be a valid measure of emptying in prio r studies as was the 4 kDa FITC dextran for gastrointetsinal absorp tion (Aube et al., 2006; Thorball, 1981). Since there is a theoretic possibility that there is a potential confounding by the action of BNP on arterial permeability and distribution of the dextran to the third space (rather than GI tract permeability or absorption) we measured and compared plasma fluorescence after intravenous inject ion of 4 kDa FITC-dextran in BNP treated and control animals. This av oids the potential confounding and validates our measurement.
RESULTS Intragastric Pressure and Gastric Contractility A typical intragastric pressure wave pattern is shown in figure 5; gastric contraction frequency averaged 3-7 times per minute ranging from 0.5 to 10 mmHg in amplitude. Figure 5. Typical pressure wave pattern of a basal gastric contraction A recording of a basal pressure pattern in windaq file is shown above. Division width = 4 seconds and division height =1 mmHg. Recording shown is a 10x compression (approximately 3 minutes) view of an actual experiment 39
Figure 6. Simultaneous recording of blood pressure and intragastric pressure Two channel recording in our data acquisition system windaq, Top panel shows blood pressure and bottom panel shows intragastric pressure. Note; division heights are 6.25 mmHg in top panel and 1 mmHg in bottom panel. Division width is 4 seconds in both channels. Recording shown is 10x compression of an actual experiment. 40
The prokinetic agent gherelin was used to ascertain that these recordings from the intragastric balloon corresponded to changes in gastric motility. Administration of gherelin resulted in a marked and significant increase in intragastric balloon pressure, validating that the contraction waves recorded are that of changes in gastric contractility. Gherelin was administered in three experiments and a typical response is shown in figure 7. Figure 7. The effect of intravenous administration of Gherelin on intragastric pressure Davison width = 8 seconds and division height = 1mmHg. Arrow indicates point of injection of gherelin 41
Figure 8. Three individual experiments showing intragastric pressure after a 10 ng/g iv bolus of ANP, BNP and CNP. A N P B N P C N P Division height = 1mmHg. Division width = 300 seconds 42
As shown in figure 8, intragastric pressure was decreased after injection of any of the three natriuretic peptides, ANP, BNP or CNP and the pressure gradually returned towards the baseline values. Figure 9. Typical recording of post peptide injection gastric contraction wave pattern Gastric pressure was attenuated after injection of BNP without significant change in frequency of contraction. Also seen is a slight dip in mean arterial pressure following BNP injection. Arrow indicates point of injection. Decompressed view, image shown is approximately 1 minute. A similar effect was observed for ANP and CNP. 43
Figure 10. The effect of C-ANP 4-23 on gastric pressure Individual experiment showing no change in gastric pressure or blood pressure when the specific NPR-C ligand cANP 4-23 was injected in to wild type mice at 10 ng/g body weight iv. Division width =80 seconds 44
Figure 11. BNP did not change gastric pressure in NPR-A knock out mice NPR-A knock out mice did not show decreased intragastric pressure with any of the natriuretic peptides. Here BNP was administered at 10 ng/g body weight iv. We quantified the change in intragastric pressure by averaging the difference between the peak and baseline gastric pressures for three thirty minute periods; before, immediately after and later than 5 peptide half-lives after peptide injection. 45
Figure 12. Determination of baseline and peak intragastric pressure before and after peptide injection Since each experimental animal had different baselines; comparing the difference between baseline and peak (i.e., the change in amplitude of the gastric contraction wave) was found to be more precise and reliably comparable among different experimental animals. The basal pressure was defined as the lowest pressure immediately before a peak and the peak was determined by moving the cursor and recording the highest point of the peak pressure. 46
47 Figure 13 (below) shows the pooled data on comparison of the average gastric pressure before peptide injection (Basal), immediately following peptide injection and later than 5 BNP half-lives (Recovery) vs. vehicle. As shown, BNP sign ificantly decreased intragastric pressure from a basal value of 2.26 0.29 mmHg to 1.44 0.11 mmHg and gastric pressure returned to 2.08 0.17 mmHg when measured later than 5 BNP half-liv es (n=5, p<0.05, ANOVA, Fishers LSD test). Similar and statistically significant reduction of gastric pressure was obtained for ANP an d CNP (Figures 14 and 15). ANP significantly decreased gastric pressu re from a basal value of 2.11 0.3 mmHg to 0.7 0.25 mmHg and CNP decreased gastric pressure from a basal value of 1.91 0.3 mmHg to 0.85 0.24 mmHg. Average gastric contractions per mi nute were 4.4 0.7, 3.1 0.4 and 4.3 0.5 for periods of BNP inject ion compared to 5.3 1.2, 4.2 0.6 and 4.3 0.5 for the vehicle group (all p>0.05, ANOVA).There was no difference in gastric pressure in BNP treated vs. vehicle treated NPR-A KO mice.
Figure 13. Mean reduction in intragastric pressure following intravenous BNP injection Basal Post injection Recovery Intragastric Pressure(mmHg) 01234 BNP Control Mean reduction in intragastric pressure (measured in mmHg) following intravenous BNP 10 ng/g in 100 l of vehicle vs. 100 l of vehicle injection to WT mice (n = 5 in each group). Intragastric pressure measured before (Basal), immediately after (Post Injection) and more than 5 peptide half-lives after injection (Recovery) is shown. BNP significantly (* = p < 0.05, ANOVA, Fishers LSD test) decreased intragastric pressure compared to vehicle. Gastric pressure returned toward basal levels when measured later than 5 BNP half-lives. 48
Figure 14. Mean reduction in intragastric pressure following intravenous ANP given at a dose of 10 ng/g body weight Basal Post injection Recovery Intragastric Pressure(mmHg) 01234 ANP Control Mean reduction in intragastric pressure (measured in mmHg) following intravenous ANP 10 ng/g in 100 l of vehicle vs. 100 l of vehicle injection to WT mice (n = 5 in each group). Intragastric pressure measured before (Basal), immediately after (Post Injection) and more than 5 peptide half-lives after injection (Recovery) is shown. 49 ANP significantly (* = p < 0.05, ANOVA, Fishers LSD test) decreased intragastric pressure compared to vehicle. Gastric pressure returned toward basal levels when measured later than 5 ANP half-lives.
Figure 15. Mean reduction in intragastric pressure following intravenous CNP given at a dose of 10 ng/g body weight Basal Post injection Recovery Intragastric Pressure(mmHg) 01234 CNP Control Mean reduction in intragastric pressure (measured in mmHg) following intravenous CNP 10 ng/g in 100 l of vehicle vs. 100 l of vehicle injection to WT mice (n = 5 in each group). Intragastric pressure measured before (Basal), immediately after (Post Injection) and more than 5 peptide half-lives after injection (Recovery) is shown. CNP significantly (* = p < 0.05, ANOVA, Fishers LSD test) decreased intragastric pressure compared to vehicle. Gastric pressure returned toward basal levels when measured later than 5 CNP half-lives. 50
Gastric Emptying Gastric emptying was measured by gavage feeding a 0.1 ml of 2.5 mmol 70 kDa FITC labeled dextran to conscious mice immediately after a 10 ng/g body weight bolus of BNP. The mice were sacrificed 30 minutes after gavage and the amount of fluoresce that has emptied the stomach as a percent of total fluorescence measured in the entire GI tract was calculated and compared between the BNP treated vs. vehicle treated mice. Figure 16. The effect of BNP on gastric emptying Wild TypeVehicle BNP Percent Gastric Emptying 60708090100 NPR-A KnockoutVehicle BNP Percent Gastric Emptying 60708090100 Percent gastric emptying, measured in amount of fluorescence that emptied the stomach as a percentage of the total fluorescence measured in the entire gastrointestinal tract 30 minutes after gavage feeding of 0.01 ml of 2.5 mmol 70 kDa FITC-dextran. BNP (10 ng/g iv) significantly decreased gastric emptying in wild type mice compared to vehicle (n =5, p < 0.05, t-test,). This effect of BNP was absent in NPR-A knockout mice (n = 5, p > 0.05, t-test). 51
Figure 17. Dose dependent reduction of gastric emptying Vehicle 5 ng/g 10 ng/g 100 ng/g Percent Gastric Emptying 406080100 ** Figure 17 shows percent decrease in gastric emptying as a function of BNP dose in WT mice. Measurements were taken 30 minutes after gavage feeding of 0.01 ml/g of 2.5 mmol FITC-dextran. Progressive doses of BNP at 5, 10 and 100 ng/g iv resulted in significant reduction of gastric emptying. (p < 0.05, n = 4 in each group, ANOVA, Fishers LSD test) 52
Absorption To measure absorption we used gavage feeding of 22ml/kg of a solution containing 22mg/ml 4 kDa FITC-dextran to conscious mice immediately following a 10 ng/g dose of BNP vs. vehicle. The plasma fluoresce (taken 1 hour after gavage) was measured and compared between the two groups. Plasma fluorescence after iv injection of FITC dextran is also measured and shown below to ascertain that the difference was not due to distribution rather than absorption. Figure 18. The effect of BNP on absorption Wild TypeVehicle BNP Relative Plasma Fluorescence 020406080100120140160180 NPR-A Knock OutVehicle BNP Relative Plasma Fluorescence 020406080100120140160180 Absorption measured in relative plasma fluorescence units one hour after gavage feeding of 4 kDa FITC-dextran in wild type mice BNP treated (10 ng/g iv) vs. vehicle (n = 5, p < 0.05, t-test). No significant difference in absorption was observed between BNP vs. vehicle treated NPR-A KO mice (p > 0.05). 53
Figure 19. Plasma fluorescence following intravenous FITCdextran, BNP vs. Vehicle Vehicle BNP Relative Plasma Fluorescnce 050100150200250300 Relative fluorescence of a 50l plasma sample taken 1 hour after intravenous administration of 100 l 0.5mmol 4kDa FITC-dextran is shown. BNP treated (10 ng/g iv) vs. vehicle in wild type mice, (p > 0.05, n = 4 in each groups, t-test). 54
55 Mean arterial blood pressure was continuously monitored during all experiments using an intra-caro tid catheter. There was a slight reduction of average blood pressu re from 62.9 4.7 mmHg prior to BNP injection to 59 3.2 mmHg (n =5, p>0.05, ANOVA, Fishers LSD test). Blood pressure returned to 61.4 5.08 mmHg when measured later than 5 peptide half-lives. Similar drops in blood pressure were also observed during the first few minutes after injection of both ANP and CNP with return of blood pressure towards baseline. Plasma BNP levels averaged 4500 pg/ml and the levels fell to 725 pg/ml at 30 minutes post injection and to undetectable levels at 90 minutes post injection.
56 DISCUSSION These experiments show that the natriuretic peptides tested, namely ANP, BNP and CNP all decrease s intragastric pressure (gastric contractility) in anesthetized mice. Prior studies have shown that natriuretic peptides decrease cont ractility of isolated gastric and intestinal smooth muscle cells in vitro (GuoCui et al., 2003; Yasuda et al., 2000), this study is the first to show this effect to be true in the whole intact animal. Furthermore, the inhibitory effects of the natriuretic peptides appears to be dose dependent and mediated primarily by NPR-A. We further investigated whether th is effect on contractility has a functional significance in the whole animal. To accomplish this we focused the subsequent studies on the effect of BNP on gastric emptying and absorption; with its increasing utility in the diagnosis and treatment of heart failure, further characterization of an aspect of BNP is deemed to be potentially of important translational benefit. Our findings confirmed that this effect of BNP on contractility is accompanied by significant reduction in gastric emptying and gastrointestinal absorption; clearly demonstrating that this inhibitory effect on the gastrointestinal tract has functional significance in the whole animal.
57 As shown in Figure 19, plasma fluorescence one hour after iv administration of 4 kDa FITC-dextr an was similar in BNP treated vs. vehicle. This finding further stre ngthens our conclusion that the reduced plasma fluorescence in gava ge fed and BNP treated mice was indeed due to decreased absorption or permeability in the GI tract and not due to other known actions of BNP such as increased renal excretion or change in vascular re distribution (Huxley et al., 1987). Although there has been some indication that natriuretic peptides are involved in inhibitory regulation of GI function (Ebert, 1988; Olsson & Holmgren, 2001), our findings are the first to document a specific inhibitory role for BNP on emptying and absorptive functions in the GI tract. The average plasma BNP levels immediately after injection averaged 4500 pg/ml. While this level is supra-physiological, it is not uncommon in patients with heart failure (Fitzgerald et al., 2005). Furthermore, even much higher leve ls of BNP are consistently seen when recombinant BNP (Nesiritide) is administered for the treatment of heart failure (Colucci et al., 2000). Moreover, the BNP level in our experiments fell to levels routinely s een in heart failure patients at 30 minutes post injection. Therefore, our experimental model provides novel insight into what would be expe cted in heart failure or when BNP is exogenously administered.
58 Natriuretic peptides bind to transmembrane receptors that have guanylyl cyclase (GC) activity. A NP and BNP bind to NPR-A where as CNP binds to NPR-B. The ensuing peptide receptor interaction increases intracellular cGMP with subsequent enzymatic steps that regulate cellular functions in vari ous tissues where these peptides and/or receptors are expressed (Kuhn, 2005). In our study, NPR-A KO mice did not show a significant response with any of the peptides we used (ANP, BNP, CNP or c-ANP 4-23 ). This suggests that; the gastrointestinal effects of BNP and the other natriuretic peptides are likely to be specifically mediated by the NPR-A receptor. Since c-ANP 4-23 specifically binds to NPR-C (AnandSrivastava, 2005), the absence of a GI effect when c-ANP 4-23 was injected into WT or NPR-A KO mice is additional evidence that NPR-A may be the major receptor mediatin g the effect of BNP on gastric emptying and absorption. Our findin g is consistent with previous studies that have shown that the inhibitory effect of CNP on isolated gastric smooth muscle cells is mediated by a cGMP-dependent pathway (GuoCai et al., 2003; Scotland et al., 2005). The natriuretic peptides in gene ral are among some of the most evolutionarily conserved peptid es across many species of the phylogenetic tree with various functi ons in fluid homeostasis. Studies done early in the discovery of natriu retic peptides have reported that
59 ANP significantly decreased jejunal fl uid absorption in dogs and rats (Morita et al., 1992; Scott & Maric, 1991). More recent studies have shown that natriuretic peptides ca use upregulation of aquaporin 3 expressions in human colonic epithelia signifying their potential role in fluid homeostasis (Pacha, 2000). A NP has also been shown to be important in promoting sea water adaptation in eels and decreases intestinal sodium absorption (T sukada et al., 2005). However, the great majority of recent studies done on BNP have focused on its role in modulating blood pressure, diuresis and natriuresis. Since the primary stimulus for release of ANP and BNP is mechanical stretch of the atrial and ventricular myocardium their expression and release is closely linked to body fluid volu me status (Cowie & Mendez, 2002; James et al., 2005). Moreover, the temporal pattern of expression and release of BNP following a given stim ulus, such as an acute myocardial infarction, indicates that the endocrine heart could potentially employ varying plasma levels of the natriuretic peptides to modulate body fluid volume (Silver, 2006). Since na triuretic peptide receptors are expressed on the gastric and inte stinal smooth muscle cells, and we show that intravenously administer ed BNP decreased gastric emptying and absorption, it is logical to deduce that our finding may be an indication that the endocrine hear t employs natriuretic peptides to delay or modulate the rate and amou nt of water and solute absorption
60 from the gastrointetsinal tract. Fr om a physiological stand point the effect of cardiac hormones on absorpti on in the GI tract is a beneficial extension of their role in volume homeostasis. Theoretically, such a role could extend to pathophysiolog ical states such as heart failure where plasma BNP levels and volume overload progressively rise (Barclay et al., 2006) and modulation of volume status becomes even more critical for survival. We have shown that high plasma levels of BNP (sustained levels of 500 pg/ml or greater), signific antly decrease gastric motility, emptying and absorption in mice. Th is appears to be a common effect of the natriuretic peptides shared by ANP and CNP. The absence of this GI effect in receptor knockout mice and the dose-response relationship suggests a receptor mediated specific event. While our study in the mouse mo del can not be generalized to humans, our findings that BNP signif icantly decreased gastric emptying and absorption offers valuable ne w insights into the role of the gastrointestinal tract in fluid home ostasis, especially during heart failure. First, symptoms of perturbed gastrointestinal function such as nausea, dyspepsia, indigestion and malabsorption are frequently seen in patients with heart failure wher e plasma BNP levels are markedly elevated (Krack et al., 2005; Sham sham & Mitchell, 2000). Our study suggests that some of these symptoms could at least partly be
61 attributable to the elevated BNP. Secondly, such an effect by BNP could potentially add a new area of interest and investigation in the role of the heart as an endocrine organ. While there are established physiological and pathophysiological cardio-renal regulatory pathways; a possible cardio-gastric and/or card io-intestinal link via natriuretic peptides appears to be anothe r possible pathway involving the endocrine heart.
62 CHAPTER FOUR THE ROLE OF BNP IN THE GASTRROINETESINAL MANIFESTATION OF MYOCARDIAL INJURY INTRODCUTION Prior studies have utilized myocardial injury models to study pathophysiological and histological effects exerted by the natriuretic peptides on the cardiova scular system. Based on the results of our experiments reported in the earlier chapters, mainly the fact that the natriuretic peptides in gene ral and BNP in particular decrease gastric emptying and absorption; we postulated that these peptides would have a similar effect in the face of acute myocardial infarction. The most commonly used methods of inducing experimental ischemia or myocardial infarction (MI) in mice are the permanent ligation of left anterior descending (LAD) coronary artery and the Cryoinfarction (freeze-thaw) method. In LAD ligation, the artery is tied with surgical sutures whereas in cr yoinfarction a blunt frozen metallic probe is directly applied to a spec ific area of the myocardium with resulting thermal ischemia at th e point of contact and surrounding
63 myocardium. Although the cryoinfarc tion method was introduced as early as 1948 (Hass & Taylor, 1948) it is only recently that it is shown to have several advantages over LA D ligation; as the LAD method is associated with marked variability in the size of the infarct and leads to apical infarct resulting in vent ricular aneurysm (van den Bos et al., 2005). In the cryoinjury model the in farct area is limited to the anterior wall of the myocardium mo re closely resembling what is encountered in clinical practice in humans; where reperfusion therapy results in limited infarct size and chances of developing apical aneurysm are becoming increasingly less likely (Huwer et al., 1998; Roell et al., 2002; van den Bos et al., 2005). Pathophysiologically, The cryoinfarction method causes ac ute cell death probably from the mechanical process associated with thermal injury; the infarct border therefore corresponds to the size of the probe hence the improved consistency of the resulting infarction as compared to the LAD ligation method (van den Bos et al., 2005). Moreover since the cryoinfarction method has a much lower peri and post operative mortality, fewer numbers of animals will be needed for a given study. We used a cryoinfarction model as the degree and distribution of the infarct (Cell death and fibrosis ) is more consistent with the cryoinfarction as compared to the Left anterior descending artery (LAD) ligation method (Huwer et al., 1998; Roell et al., 2002).
64 This study was designed to test whether a cryoinfarction of the myocardium leads to change in ga stric emptying and absorption in mice and whether the difference in the plasma BNP levels between the MI and Sham mice is responsible for this difference. The study was also done in NPR-A knock out mice to test whether this effect is mediated by NPR-A as shown by our previous experiments.
65 RESULTS As shown in figure 20, our cryoinfarction model produced myocardial cell death and fibrosis similar to what will be seen in myocardial infarction. The infarction was limited to the area under the application of the frozen probe and immediate surrounding myocardial tissue without extension to the ve ntricular apex. AS a result no ventricular aneurysms were observed in our model. We tested and compared the degr ee of gastric emptying at one and two week after infarction to es tablish the differences in plasma BNP levels between the MI and sh am mice. Subsequent experiments on absorption were done at two weeks after infarction. When gastric emptying was measured one week after infarction, it was significantly decreased in the cryoinfarction group as compared to the sham. Percent gastric emptying was 67.5% 5.8 for the MI group vs. 88.7% 2. 9 for the sham group (P<0.05, t-test) as shown in figure 21. The plasma BNP levels were elevated in both groups but significantly higher in the MI group as compared to the sham group. BNP levels were 4292.2 276.5 1 week after MI vs. 105.4 11.3 in sham mice (n = 5, p<0.05, t test). BNP levels were 1964.7 755 two weeks after MI, (n=5, p<0.05, t test compared to one week post MI).
Figure 20. Representative histological appearance of the myocardium14 days after cryoinfarction. Stain: Hematoxylin & Eosin 4x (Top); 20x of the boxed part (Bottom) LV Wall LV Ca v i ty 66
Figure 21. Comparison of percent gastric emptying in sham vs. MI in Wild Type mice; one week after cryoinfarction Sham MI Percent Gastric Emptying 020406080100 ** WT mice, 67.5% 5.8% for mice with MI vs. 88.7 2.9 % for sham (n=7, P<0.05) 67
Figure 22. Comparison of percent gastric emptying in sham vs. MI Wild Type mice, two weeks after cryoinfarction Sham MI Percent Gastric Emptying 5060708090100 WT mice, 82.2% 0.5% for mice with MI vs. 97.9 0.4 % for sham (n=5, P<0.05) P= 0.017. As shown in figure 22 above, two weeks after infarction, percent gastric emptying values were also significantly lower in the MI group as compared to the sham group 82.2% 0.5% for MI vs. 97.9 0.4 % for sham (n=5, P<0.05). 68
Figure 23. Comparison of Percent gastric emptying in sham vs. MI NPR-A KO mice, two weeks after cryoinfarction Sham MI Percent Gastric Emptying 5060708090100 KO mice, 84.6% 0.7% for mice with MI vs. 87.6 054 % for sham (n=6, P >0.05) P= 0.07 In NPR-A knock out mice, percent gastric emptying was identical between the MI vs. the sham group 84.6% 0.7% for mice with MI vs. 87.6 054 % for sham (n=6, P >0.05). 69
There was also a statically significant difference in the degree of absorption measured in relative fluorescence units (RFU) in the plasma following a gavage meal containing 22ml/kg of 22mg/ml 4 kDa FITC dextran. In wild type mice, absorption was, 631.9 121 (RFU) for the MI group vs. 349.8 78.6 (RFU) for the sham group; n=6, P< 0.05. Figure 24. Comparison of absorption measured in relative Plasma fluorescence units. Sham vs. MI, WT mice Sham MI Relative Fluorescence Units(Plasma) 0200400600800 Absorption measured in Relative plasma fluorescence units WT mice, 631.9 121 for mice with MI vs. 349.8 78.6 for sham n=6, P< 0.05 (P=0.04) 70
In NPR-A knockout mice the difference in absorption was not statistically significant. Absorption measured in Relative plasma fluorescence units in NPR-A KO mice was, 516.2 107.3 for mice with MI vs. 366.5 39 for sham n=6, P> 0.05 (P=0.1). Figure 25. Comparison of absorption measured in relative plasma fluorescence units. Sham vs. MI, NPR-A KO 71 Sham MI Relative Fluorescence Units(Plasma) 0200400600 800 Absorption measured in Relative plasma fluorescence units NPR-A KO mice, 516.2 107.3 for mice with MI vs. 366.5 39 for sham n=6, P> 0.05 (P=0.1).
72 DISCUSSION The presence of dyspeptic sympto ms in heart failure and during acute myocardial ischemia has been known for a long time. Studies done as early as 1966 have report ed what was then described as venostatic gastritis where venous congestion is believed to be the cause of gastric pathology (Fixa et al., 1966). The presence of nausea, vomiting and indigestion during acut e myocardial infarction and in the course of heart failure has also been extensively reported in the literature (Abrahamsson & Thor n, 1973; Ahmed et al., 1978; Camura et al., 2004; Pasini et al., 1989; Wei 1988). Studies that have looked into mechanisms of such an association have in the past mainly pointed to a possible chemor eceptive or neurally mediated reflex known as the Bezold-Jarish refl ex (Chianca et al., 1997; Sleight, 1981). Both ANP and BNP have previo usly been shown to have cardioprotective effect during acute myocardial infarction. For instance, the effect of ANP and BNP on renal salt handling was shown to be specifically enhanced during acute myocardial ischemia irrespective of the level of acti vation of the renin angiotensin aldosterone (RAS) system (Charles et al., 2003; Rademaker et al., 2000). ANP was also shown to have im portant volume regulation role
73 during acute heart failure induced by ventricular pacing (Lee et al., 1989). Both BNP and ANP are also shown to have an inhibitory effect on regional sympathetic activity in the kidney and the heart (BrunnerLa Rocca et al., 2001). While the pa thways that lead to sympathetic activity are not clearly understood, the end result of decreased sympathetic activity is cardioprotec tive. Studies that looked at the receptors involved in such proces ses have consistently shown that these effects are mediated by cGMP coupled pathways. While some of this effect is indirectly mediated via the renin angiotensin aldoseterone (RAS) system, protective actions of guanylyl cyclase-A that are not mediated by the RAS have also been shown (Li et al., 2002; Nakanishi et al., 2005). In our experiments, we tested the effect of acute myocardial injury on gastric emptyi ng at one and two week s post infarction and compared the results along with th e plasma BNP levels. There was a significant reduction in gastric empt ying at one week in mice with myocardial infarction compared to sham. It is interesting to note that even the sham mice had a slightly lower rate of gastric emptying at one week compared to controls (bas eline values). As the BNP levels were higher in sham mice than in controls, and the levels were markedly higher in the infarcted mice than the sham mice, this is an indication that BNP levels corresp onded with the degree of gastric
74 emptying. At two weeks post infarc tion, the sham mice had gastric emptying statistically identical to controls where as infarcted mice continue to show a markedly lower rate of gastric emptying, this again indicates that the BNP levels signif icantly correspond with the degree of gastric emptying adding eviden ce that BNP may be the major (or one of the major) reasons for the observed differences. Since our data shows that infarcted receptor kn ock out mice had no significant difference in gastric emptying comp ared to sham, this validates our assertion that the BNP difference played a role in the observed effect and this effect is probably mediated through the NPR-A receptor. Our absorption data for wild type mice is consistent with our central hypothesis and infarcted mice did show significantly lower absorption rate as comp ared to sham. The data in the knock out mice in our experiment is less conclusive since the knock out mice with MI did show a reduced absorption comp ared to the sham mice. There are several explanations for this finding. First of all, myocardial injury is known to activate a series of systems other than the natriuretic peptides, and secondly the process of absorption in the GI tract is also likely to involve several different mechanisms. For instance the renin angiotensin aldoseterone system is known to be activated with myocardial injury, inflammatory mediators such as tissue growth factor and tumor necrosis factor are al so a few of the cytokines that
75 are released from infarcted myocar dium and circulate in the plasma with potential effects in the GI trac t. Therefore the ob served effects in NPR-A knock out mice may be manife stations of activation of these systems that would be expected to be intact in the NPR-A knock out mice. It has also been shown that intravenous volume expansion decreased gastric emptying and perm eability of the mucosa to water and solutes and vagus nerve mediated neural mechanism were postulated as mechanisms for such an effect (Chang EB and Rao MC., 1994). It was also reported that acute blood volume expansion with intravenous fluids decreased net sodium absorption in the jejunum of rats and dogs (Duffy et al., 1978; Richet & Hornych, 1969). Moreover experiments in human volunteers ha ve shown that body position changes such as recumbency and simu lation of hemorrhage resulted in significant increase in intestinal wa ter and salt absorption (Sjvall et al., 1986). Despite this known relationship between gut motility, gastric emptying and intestinal absorption on one hand and intravenous venous expansion and co ntraction on the other, most of the studies that have investigated th is relationship were limited to the vagal or sympathetic nervous system. Nevertheless, with the knowledge base accumulated in the field of natriuretic peptides over the past two decades, it is only logi cal to conjecture that at least some
76 of the changes observed in gastric em ptying and intestinal absorption during acute MI or heart failure may be due to natriuretic peptides. The data supporting the relationship between volume expansion and gastric emptying and intestinal wa ter and salt absorption is fairly strong. What was missing was an experiment to directly and specifically test whether the elevated natriuretic peptide levels (caused by volume expansion or myocardial injury) corresponded with gastric contractility, gastric emptying an d absorption. Together with our earlier findings that all the natriuretic peptides significantly decrease gastric contractility, our data on BNP showing significant reduction of gastric emptying and absorption; the confirmation of these findings in an acute myocardial infarction model is a strong indication that plasma BNP (and natriuretic peptide) elevation during acute MI and / or heart failure is at least partly responsi ble for these observed effects. More importantly, the previously confirmed effect of increased plasma volume on gastric emptying and absorp tion is validated by our data to be mediated by natriuretic peptides in general and by BNP in particular. This finding strengthens the case for a humoral link between the heart and the GI tract and opens up new avenues for heart failure research. We believe further research in this area could identify potential new targets for the treatment of heart failure.
77 CHAPTER FIVE BNP AND NON MUSCLE MYOSINS IN THE GASTROINTETSINAL TRACT INTRODUCTION Myosins are proteins that are involved in mechanical force generation and transduction. The characteristic myosin molecule is composed of two heavy chain subu nits measuring approximately 200 kDa each, which form a globular amino-terminal head region, and a coiled carboxyl-terminal tail. The globular head region is noncovalently associated with two pair s of light chains of 20 and 17 kDa (Kelley & Adelstein, 1990). Typically myosins interact with another protein; actin, in a process that involves the hydrolysis of ATP. Classically such actomyosin interact ion is discussed in the context of muscle contraction and relaxation. However myosins are also expressed in non muscle tissue (Sellers, 2000).
Figure 26. Schematic diagram of non muscle myosin-II Adapted from Bresnick (1999) In non muscle cells, the prototype non muscle myosin type-II regulates actin organization into filaments and its functions include maintaining the cell shape, cell division and cell movement (Bresnick, 1999). Non muscle myosin-II is also involved in epithelial cell attachment at the tight junction regulating paracellular permeability (Hecht et al., 1996). Tight junctions are integral part of the intestinal villi absorptive structures. 78
Intestinal Villi Figure 27. Schematic depiction and electron micrograph of the structures of intestinal villi 79 Adapted from Keith R. Porter and S Clark The electron micrograph (above) shows the microvilli of a mouse intestinal cell. Incorporated in the plasma membrane of the microvilli are a number of enzymes, mucous producing goblet cells and endocrine / paracrine cells that produce a number of hormones, among which are the natriuretic peptides and guanylins.
Figure 28. Cytoskeletal structures of the intestinal microvillus. Adapted from Ross, Histology: A Text and Atlas, 4th ed. 80
Figure 29. Ultra structures of the microvilli cytoskeleton A B Adapted from (Hirokawa & Heuser, 1981) Actin cytoskeleton is shown by the arrow(s) in panel A, and in panel B the quick freeze, deep etch, rotary replication images show the core of the microvilli and its attachment at the cytoskeleton base in the cytoplasm 81
Figure 30. Transmission Electron micrograph of intestinal villi in various state of contraction Chicken intestinal epithelia showing increasing state of contraction (top to bottom). Note fanning of the microvilli as the degree of contraction increase. Transmission electron micrograph. Top; 6100x, middle; 5600 x and bottom 8900x. Adapted from (Burgess, 1982) 82
Tight Junctions Tight junctions seal adjacent epithelial cells in a narrow band just beneath their apical surface. They perform vital functions including regulation of the passage of molecules and ions through the space between cells and blocking of movement of the integral membrane proteins between the apical and basolateral surfaces. Figure 31. Schematic depiction of tight junctions Studies done in kidney, bladder and intestinal epithelia have confirmed changes in permeability regulated by Phosphorylation related contractile changes at the tight junction. These changes primarily increase paracellular movement of water and small molecular weight solutes (Broschat et al., 1983; Hecht et al., 1996; Keller & Mooseker, 1982; Swanljung-Collins & Collins, 1992). Non muscle myosin type IIB is phosphorylated 83
84 by casein kinase-II and dephosph orylated by a phosphatase that is regulated through the action of Rhoassociated kinase (Li & Gorodeski, 2006). Since the physiological effects of the natriuretic peptides are mediated via cGMP dependant protein kinases, we found it intriguing to examine whether tr eatment with BNP would reveal changes in the distribution of non muscle myosins and contractility pattern of the intestinal villi and thus shed some light on the mechanism for the observed effect of BNP on absorption. We treated wild type mice with a 10 ng/g iv bolus of BNP followed by a 1ng/minute infusi on for 30 minutes. After the 30 minute infusion the mice were sacrificed and intestinal tissue removed and sectioned into, jejunum, ileum and colon and immunostained for non muscle myosin as described in the methods section. We used the vehicle as an experimental control. We also used a tissue section not treated with first antibody as a methodological co ntrol to evaluate the potential confounding by non specific binding.
RESULTS Figure 32. Toluidine blue stained 3m sections of a mouse intestinal tissues 85 Cross sections of intestinal tissue from our experiments are shown. Top panel, Jejunum; middle panel, ileum; and bottom panel, colon.
Figure 33. Higher magnification view of intestinal villi Images shown are 3 m section of Jejunal villi (top) and Ileum (bottom), stained with toluidine blue. Magnification is 40x top, and 20x bottom. 86
Figure 34. Electron micrograph of the intestinal microvilli Control vs. BNP treated Control, 20 000x BNP treated, 20 000x Microvilli in BNP treated mice show loss of the distinctive fanning of the microvilli that is typical of markedly contracted state. 87
Figure 35. Jejunal villi immunostained for non muscle myosin type IIB Control Longitudinal section at 20x (Top) and cross section 40x bottom 88
Figure 36. Comparative images of control vs. BNP treated jejunal villi Images show jejunal villi, immunostained for non muscle myosin type IIB. Control (TOP) and BNP treated (bottom). Note the marked increase in fluorescence in BNP treated as compared to control. Immunofluorescence, 20 x magnification. 89
Figure 37. Jejunal villi and smooth muscle bundles immunostained for non muscle myosin Cross section view of the mouse ileum is shown. Note the circular and longitudinal smooth muscle bundles with distinct stain (fluorescence) for non muscle myosin type IIB. The core of the villi also shows the distinct staining pattern. Magnification, 10 x 90
Figure 38. A 3 m sections of a mouse jejunum immunostained for non muscle myosin type IIB. Control vs. BNP Control top and BNP treated bottom. Note the markedly increased staining of the villus core and the crypt in BNP treated mouse. 20x 91
92 DISCUSSION Structures necessary for force generation and mechanotransduction such as actin and myosin and their associated proteins are integral components of the cytoskeleton of the intestinal villi (Mooseker 1976; Mooseker et al., 1983; Rodewald et al., 1976; Rostg aard & Thuneberg, 1972). Although the mechanism of contraction of intestinal villi still remains unsettled, different studies have reported mechanisms of contraction that are both ATP and calcium dependent and others reporting calcium independent mechanisms of contraction (Burgess, 1982; Mooseker, 1976; Swanljung-Collins & Collins, 1991). Still other studies have repo rted contraction at the tight junctions but not of the microvilli themselves (Keller & Mooseker, 1982). Our electron micrograph ic observations indicate that elevation of BNP in the plasma appears to cause the microvilli to loose the typical fanning or separated appearance that is characteristic of contraction at th e crypt region of the intestinal microvilli. Such appearance was pr eviously shown to be due to contraction at the tight junction regions involving a circumferential contractile ring (Burgess, 1982). Tight junction
93 contraction in turn results in increased paracellular permeability (Hecht et al., 1996; Turner et al., 1997). Therefore our electron micrographic observation (decreased contraction of the tight junction contractile ring) supports the hypothesis that elevated BNP in the plasma makes the tight junctions of intestinal villi less permeable to water and small molecular weight solutes. Our fluorescence immunostaining images also support this hypothesis as we show enhanc ed distribution of non muscle myosins along the crypts of the v illi; which may be an indication that the enhanced distribution corresponds to a change in tautness of the tight junctions thereby decreasing paracellular movement while allowing apical transport of nutrients. Apical transport of electrolytes and nut rients (sodium and glucose for example) is mediated by the sodium glucose cotransporter (SGLT1) and is accompanied by increased tight junction permeability to small solutes (Turner et al., 1997). Physiologically such coordination between the apical and basolateral surfaces of the villu s would be advantageous; as it allows regulated (transporter me diated) absorption across the apical membrane while directing water and small solutes to the tight junction. However whenever there is a need to decreases volume, as in the case of heart failure; decreasing free
94 paracellular movement of water while still permitting apical transport of nutrients would allow for a more homeostatic absorptive function; especia lly when modulating volume becomes essential as in the case of heart failure. Utilizing BNP and possibly the other natriuretic peptides for this process would have physiological benefit for the heart; after all the heart will be interested in getting all the nut rients it can get during heart failure while delaying or decreasi ng absorption of water and salt that could add to its stress. Although the effect of B NP and natriuretic peptides in general on permeability of inte stinal epithelia has not been extensively studied in the past, it is known that natriuretic peptides in general have an effect on permeability of the vascular epithelium (He et al., 1998; Huxley et al., 1987; Kubes, 1993; Lofton et al., 1990). Studies that have looked into this effect of ANP and BNP on perm eability of pulmonary vascular epithelium have shown that these effects were at least partially reproduced by cGMP or cGMP analogs (Draijer et al., 1995; Hlschermann et al., 1997; Klinger et al., 2006; Westendorp et al., 1994). A more direct effect th at is independent of cGMP was also shown for ANP (Kubes, 1993). Similarly, other studies that have investigated the effect of ANP on counteracting the
95 endothelial permeability and in flammatory effect of tumor necrosis factor (TNF) have shown that this effect is mediated by NPR-A and cGMP and it is targeted at cytoskeletal actin organization (Kiemer et al., 2002) An other support for this finding comes from the observation that vascular endothelial growth factor (VEGF) is inhibited by ANP (Pedram et al., 2002). VEGF is also known as vascula r permeability factor and is involved in stabilization of actin association with tight junctions; and this function was reversed by guanylyl cyclase receptor antagonists (Pedram et al., 2002). The precise mechanism of this process is still unclear, some studies indicated it involves heat shock protein 27 (HSP27); a protein with known functions in actin organization and whos e actions are mediated by cGMP dependent protein kinase (Butt et al., 2001). Other studies suggest mechanisms that involve Phosphorylation of structural and contractile proteins; includin g actin and myosin (Hecht et al., 1996; Ma et al., 2000; Turner et al., 1997), Specifically at the prejunctional ring of actin and myosin; sites that are characteristic of contractile functi on at the tight junction (Madara et al., 1987). Our immunofluorescene images revealed an enhanced distribution of non muscle myosins in the intestinal villi core and
96 along the crypts (tight junctions). While we havent done biochemical analysis to correspon d with these findings, previous studies have shown that Phosphorylation related proteins such as mitogen-activated protein (MAP) kinase and Rho of the ras family of proteins are associated with tight junctions and this in turn controls tight junction co ntractility (Murakami et al., 1994; Zahraoui et al., 1994). Interest ingly, both ANP and BNP are known to exert anti inflammatory (thus decreased vascular endothelium permeability) effects in vascular endothelium through mechanisms that involve MAP-kinase and MAP kinase phosphatase-1 (MKP-1) (Frst et al., 2005; Weber et al., 2003). Although more research needs to be done in this direction, our electron micrographic imag ing and immunostaining data coupled with what is previously known about epithelial tight junction function lends enough support to our hypothesis and helps formulate a basis for future direction. The finding that immunostaining of non muscle myosin in BNP treated mouse tissue shows enhanced distribution of non muscle myosins along the crypts and core of the intest inal microvillus appears to be a recurring theme. Tight junctions appear to contract less and microvilli assume the typical noncontracting appearance when BNP plasma level was raised. Thes e findings are associated with
97 decreased paracellular permeability at least in the case of the vascular endothelium. Whethe r the biochemical signaling mechanisms known for vascular endothelium will be the same in the intestinal villi and whether it will have similar physiological consequences remains to be investigated.
98 CHAPTER SIX SUMMARY AND CONCLUSIONS The main objective of my study wa s to show that there indeed is a humoral link between the heart and the gastrointestinal system. This humoral link appears to utilize natriu retic peptides although it is possible that there probably are several other as yet undiscovered peptides or even other molecules th at serve this same purpose. To this aim, we demonstrated that ANP, BNP and CNP decreased contractility of gastric smooth muscle in the whole intact animal. Confirming the previously done in vitro experiments that showed natriuretic peptides decreased cont ractility of isolated gastric and intestinal smooth muscle cells. This effect was shown to have a functional significance in that; th ese experiments showed that gastric emptying and absorption from the gut were decreased in the whole animal when BNP was intravenously administered. We also presented data showing myocardial injury and th e associated elevation in plasma BNP levels decreased gastric emptying and absorption from the GI tract. Although the obvious reason fo r this result may be the effect of BNP on smooth muscle relaxation, we also show data supporting the
99 hypothesis that BNP and natriuretic pe ptides have a more direct effect on absorptive structures of the intestinal villi possibly affecting paracellular transport of water and electrolytes. In summary one can garner th e following observations from these experiments a) Natriuretic peptides decrease gastric contractility and gastric emptying in inta ct whole animals b) BNP decreased gastric empting in a dose dependant manner c) BNP decreased absorption from th e GI tract when administered at dose designed to raise the plasma level to the levels seen in heart failure d) Myocardial injury and elevation of BNP in the plasma was associated with decreased gastric emptying and absorption e) Elevated plasma BNP has en effect on contractile structures of the intestinal villi and this effect appears to be directed at decreasing paracellular movement of water and solutes
100 PERSPECTIVES The next line of research should follow the intriguing questions raised by our immunofluorescnece data. How and why does the distribution of myosin in the microv illi appear to be increased by BNP? What are the molecular mechanisms that are involved here? Is the electron micrograph appearance of microvilli indication of contraction at the tight junction? Is paracellu lar movement of water and solutes decreased by BNP as suggested by our imaging data? Are there other transporters that direct water and sodium absorption to the basal and apical membranes; if so can they be therapeutically targeted to regulate sodium absorption from the gut? Would that be beneficial in heart failure treatment? Heart failure remains to be a ma jor public health problem. Its annual cost to the health care field is growing every year and currently stands at over 30 Billon US dolla rs. Despite remarkable advances in the treatment of coronary disease an d the risk factors associated with it, the incidence and prevalence of he art failure has only increased. In spite of all this, there hasnt be en a major breakthrough in heart failure treatment for many decades. Of course targeting the gut to
101 treat the heart seems a bit far fetche d at this point in time. However, the GI tract is a complex organ, pe rhaps even tantamount to having many organs in one. The experi mental results presented here strengthen the case for a direct humoral link and interplay between the heart and the GI tract. Furthe r understanding of this link and characterization of the signaling pr ocess involved is likely to be a major advance in heart failure treatment.
102 REFERENCES CITED Abrahamsson, H., & Thorn, P. (1973). Vomiting and reflex vagal relaxation of the stomach elicit ed from heart receptors in the cat. Acta Physiol Scand, 88(4), 433-439. Ahmed, S. S., Gupta, R. C., & Bran cato, R. R. (1978). Significance of nausea and vomiting during acute myocardial infarction. Am Heart J, 95 (5), 671-672. Anand-Srivastava, M. B. (2005). Natriuretic peptide receptor-C signaling and regulation. Peptides, 26 (6), 1044-1059. Anand-Srivastava, M. B., & Trachte, G. J. (1993). Atrial natriuretic factor receptors and signal transduction mechanisms. Pharmacol Rev, 45(4), 455-497. Anderson, J. V., Donckier, J., McKenna, W. J., & Bloom, S. R. (1986). The plasma release of atrial natriuretic peptide in man. Clin Sci (Lond), 71 (2), 151-155. Antunes-Rodrigues, J., McCann, S. M. Rogers, L. C., & Samson, W. K. (1985). Atrial natriuretic factor inhibits dehydrationand angiotensin II-induced water intake in the conscious, unrestrained rat. Proc Natl Acad Sci U S A., 82 (24), 8720-8723. Aube, A. C., Cabarrocas, I., Bauer, J., Philippe, D., Aubert, P., Doulay, F., Liblau, R., Galmiche, J. P., & Neunlist, M. (2006). Changes in enteric neurone phenotype and intestinal functions in a transgenic mouse model of enteric glia disruption. Gut, 55 (5), 630-637.
103 Barclay, J. L., Kruszewski, K., Croal, B. L., Cuthbertson, B. H., Oh, J. K., & Hillis, G. S. (2006). Relation of left atrial volume to B-type natriuretic peptide levels in pati ents with stable chronic heart failure. Am J Cardiol., 98 98-101. Barros, G., J.,, Vakil, N., Gutkowsk a, J., Sellin, J., & Potter, G. D. (1990). Atrial natriuretic factor and cyclic guanosine monophosphate: ion transport in rat colon in vitro and in vivo. Gastroenterology, 99 (4), 1153-1156. Beltowski, J. (2001). Guanylin and related peptides. J Physiol Pharmacol, 52(3), 351-375. Bloch, K. D., Seidman, J. G., Naftilan, J. D., Fallon, J. T., & Seidman, C. E. (1986). Neonatal atria an d ventricles secrete atrial natriuretic factor via tissue-specific secretory pathways. Cell, 47 (5), 695-702. Boerrigter, G., & Burnett, J. C. J. (2004). Recent advances in natriuretic peptides in congestive heart failure. Expert Opin Investig Drugs, 13 (6), 643-652. Bresnick, A. R. (1999). Molecular me chanisms of nonmuscle myosin-II regulation. Curr Opin Cell Biol, 11(1), 26-33. Broschat, K. O., Stidwill, R. P., & Burgess, D. R. (1983). Phosphorylation controls brush border motility by regulating myosin structure and association with the cytoskeleton. Cell, 35 ((2 Pt 1)), 561-571. Brunner-La Rocca, H. P., Kaye, D. M., Woods, R. L., Hastings, J., & Esler, M. D. (2001). Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared wi th healthy control subjects. J Am Coll Cardiol, 37 (3), 1221-1227.
104 Burgess, D. R. (1982). Reactivation of intestinal epithelial cell brush border motility: ATP-dependent contraction via a terminal web contractile ring. J Cell Biol, 95 (3), 853-863. Butt, E., Immler, D., Meyer, H. E., Ko tlyarov, A., Laass, K., & Gaestel, M. (2001). Heat shock protein 27 is a substrate of cGMPdependent protein kinase in intact human platelets: phosphorylation-induced actin po lymerization caused by HSP27 mutants. J Biol Chem, 276 (10), 7108-7113. Camura, F. D., De Queiroz, D. A ., Leal, P. R., Rodrigues, C. L., Gondim, F. A., Da Graa, J. R., Rola, F. H., Nobre e Souza, M. A., & dos Santos, A. A. ( 2004). Gastric emptying and gastrointestinal transit of liquid in awake rats is delayed after acute myocardial infarction. Dig Dis Sci, 49(5), 757-762. Carrithers, S. L., Hill, M. J., Johnson B. R., O'Hara, S. M., Jackson, B. A., Ott, C. E., Lorenz, J., Mann, E. A., Giannella, R. A., Forte, L. R., & Greenberg, R. N. (1999). Re nal effects of uroguanylin and guanylin in vivo. Braz J Med Biol Res, 32 (11), 1337-1344. Cea, L. B. (2005). Natriuretic peptide family: new aspects. Curr Med Chem Cardiovasc Hematol Agents. 2005 Apr;3(2):87-98, 3 (2), 87-98. Charles, C. J., Elliott, J. M., Nich olls, M., G.,, Rademaker, M. T., & Richards, A. M. (2003). Natriuretic peptides maintain sodium homoeostasis during chronic vo lume loading post-myocardial infarction in sheep. Clin Sci, 104 (4), 429-436. Chianca, D. A., Jr., Bonagamba, L. G., & Machado, B. H. (1997). Neurotransmission of the Bezold-J arisch reflex in the nucleus tractus solitarii of sino-aortic deafferentated rats. Brain Res, 756 (1-2), 46-51. Chinkers, M., & Garbers, D. L. (1989). The protein kinase domain of the ANP receptor is required for signaling. Science, 245 (4924), 1392-1394.
105 Chinkers, M., & Wilson, E. M. (1992). Ligand-independent oligomerization of natriuretic pept ide receptors. Identification of heteromeric receptors and a dominant negative mutant. J Biol Chem, 267 (26), 18589-18597. Clavell, A. L., Stingo, A. J., Wei, C. M., Heublein, D. M., & Burnett, J. C., Jr.,. (1993). C-type natriuretic peptide: a selective cardiovascular peptide. Am J Physiol. (264 (2 Pt 2)), R 290-295. Colucci, W. S., Elkayam, U., Horton, D. P., Abraham, W. T., Bourge, R. C., Johnson, A. D., Wagoner, L., Givertz, M. M., Liang, C. S., Neibaur, M., Haught, W. H., & LeJemtel, T. H. (2000). Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med, 343 (4), 246-253. Cowie, M. R., & Mendez, G. F. (2002). BNP and congestive heart failure. Prog Cardiovasc Dis, 44 (4), 293-321. Currie, M. G., Geller, D. M., Cole, B. R., Siegel, N. R., Fok, K. F., Adams, S. P., Eubanks, S. R., Galluppi, G. R., & Needleman, P. (1984). Purification and sequence analysis of bioactive atrial peptides (atriopeptins). Science., 223 (4631), 67-69. Date, Y., Nakazato, M., & Matsuo, H. (1998). Guanylin family: new intestinal peptides regulating salt and water homeostasis. Nippon Rinsho, 56 (9), 2427-2432. de Bold, A. J., Borenstein, H. B., Veress, A. T., & Sonnenberg, H. (1981). A rapid and potent natriu retic response to intravenous injection of atrial myoc ardial extract in rats. Life Sciences., 28 (1), 89-94. de Bold., A. J. (1985). Atrial natriuretic factor: a hormone produced by the heart. Science., 230 (4727), 767-770.
106 Depoortere, I., De Winter, B., Thijs, T., de Man, J., Pelckmans P., & Peeters, T. (2005). Comparison of the gastroprokinetic effects of ghrelin, GHRP-6 and motilin in rats in vivo and in vitro. Eur J Pharmacol., 515 (1-3), 160-168. Dietz, J. R. (1984). Release of natriu retic factor from a rat heart-lung preparation by atrial distension. 247:R1093-6, 1984. American Journal of Physiology, Regulato ry Integrative and comparative physiololgy, 247(R), 1093-1096. Dietz, J. R., Nazian, S. J., & Vesely, D. L. (1991). Release of ANF, proANF 1-98, and proANF 31-67 from isolated rat atria by atrial distension. American Journal of physiology, 260 (H), 1774-1778. Dietz, J. R., Scott, D. Y., Landon, C. S., & Nazian, S. J. (2001). Evidence supporting a physiologica l role for proANP-(1-30) in the regulation of renal excretion. Am J Physiol Regul Integr Comp Physiol, 280 (5), R1510-1517. Dietz, J. R., Vesely, D. L., Gower, W. R., Landon, C. S., Lee, S. J., & Nazian, S. J. (2003). Neutralization of proANP (1-30) exacerbates hypertension in the spontaneously hypertensive rat. Clin Exp Pharmacol Physiol, 30 (9), 627-631. Dietz, J. R., Vesely, D. L., Gower, W. R. J., & Nazian, S. J. (1995). Secretion and renal effects of ANF prohormone peptides. Clin Exp Pharmacol Physiol, 22 (2), 115-120. Dietz, J. R., & Villarreal, D. (1995). Physiological functions of atrial natriuretic factor prohormone peptides: introduction. Clin Exp Pharmacol Physiol, 22 (2), 107. Donald, D. E., & Shepherd, J. T. (1979). Cardiac receptors: normal and disturbed function. Am J Cardiol, 44(5), 873-878.
107 Draijer, R., Atsma, D. E., van der Laarse, A., & van Hinsbergh, V. W. (1995). cGMP and nitric oxide modulate thrombin-induced endothelial permeability. Regulation via different pathways in human aortic and umbilical vein endothelial cells. Circ Res, 76 (2), 199-208. D'Souza, S. P., Davis, M., & Baxter, G. F. (2004). Autocrine and paracrine actions of natriure tic peptides in the heart. Pharmacol Ther, 101 (2), 113-129. Duffy, P. A., Granger, D. N., & Ta ylor, A. E. (1978). Intestinal secretion induced by volume expansion in the dog. Gastroenterology, 75 (3), 413-418. Ebert, R. (1988). Control of gastri c emptying by regulatory peptides. Z Gastroenterol Verh, 23 165-170. Espiner, E. A., Richards, A. M., Yandle, T. G., & Nicholls, M. G. (1995). Natriuretic hormones. Endocrinol Metab Clin North Am, 24 (3), 481-509. Fitzgerald, R. L., Cremo, R., Gardetto, N., Chiu, A., Clopton, P., Bhalla, V., & Maisel, A. S. (2005). Effect of Nesiritide in Combination With Standard Therapy on Serum Concentrations of Natriuretic Peptides in Patients Admitted for Decompensated Congestive Heart Failure. Am Heart J., 150 471-477. Fixa, B., Komrkov, O., Jurkovic, V., & Herout, V. (1966). On socalled venostatic gastritis in congestive heart failure. Cardiologia, 48 (5), 471-478. Flynn TG, d. B. M., de Bold AJ. ( 1983). The amino acid sequence of an atrial peptide with potent diur etic and natriuretic properties. Biochem Biophys Res Commun., 117 (3), 859-865.
108 Forssmann, W. G., Richter, R., & Meyer, M. (1998). The endocrine heart and natriuretic peptides: histochemistry, cell biology, and functional aspects of the renal urodilatin system. Histochem Cell Biol., 110 (4), 335-357. Forte, L. R., Fan, X., & Hamra, F. K. (1996). Salt and water homeostasis: uroguanylin is a ci rculating peptide hormone with natriuretic activity. Am J Kidney Dis, 28 (2), 296-304. Forte, L. R., Freeman, R. H., Krau se, W. J., & London, R. M. (1999). Guanylin peptides: cyclic GMP signaling mechanisms. Braz J Med Biol Res, 32 (11), 1329-1336. Foster, D. C., Wedel, B. J., Robins on, S. W., & Garbers, D. L. (1999). Mechanisms of regulation and functions of guanylyl cyclases. Rev Physiol Biochem Pharmacol, 135 1-39. Freda, B. J., & Francis, G. S. ( 2006). Natriuretic peptides and renal insufficiency: clinical significance and role of renal clearance. Heart Fail Clin., 2 (3), 277-290. Frst, R., Brueckl, C., Kuebler, W. M., Zahler, S., Krtz, F., Grlach, A., Vollmar, A. M., & Kiemer, A. K. (2005). Atrial natriuretic peptide induces mitogen-activated protein kinase phosphatase-1 in human endothelial cells via Rac1 and NAD(P)H oxidase/Nox2activation. Circ Res, 96 (1), 43-53. Garbers, D. L., Chrisman, T. D., Wieg n, P., Katafuchi, T., Albanesi, J. P., Bielinski, V., Barylko, B., Redfield, M. M., & Burnett, J. C. (2006). Membrane guanylyl cycl ase receptors: an update. Trends Endocrinol Metab., 17 (6), 251-258. Gerbes, A. L., Dagnino, L., Nguyen, T., & M., N. (1994). Transcription of brain natriuretic peptide and atrial natriuretic peptide genes in human tissues. J Clin Endocrinol Metab., 78 (6), 1307-1311.
109 Gower, W. R., Jr., Dietz, J. R., Vesely D. L., Finley, C. L., Skolinck, K. A., & Fabri, P. J. (1994). Atrial natriuretic peptide gene expression in the rat gastrointestinal tract. Biochem Biophys Res Commun, 202 562-570. Gower, W. R., Jr.,, Dietz, J. R., McCuen, R. W., Fabri, P. J., Lerner, E. A., & Schubert, M. L. (2003). Regu lation of atrial natriuretic peptide secretion by cholinergic and PACAP neurons of the gastric antrum. Am J Physiol Gastrointest Liver Physiol., 284 (1), G68-74. Gower, W. R., Jr.,, & Skvorak, J. P. (1997). The gastrointestinal natriuretic peptide system: a region al system with tissue-specific and vascular components. In: Atrial Natriuretic Peptides, edited by D. L. Vesely. Trivandrum, India: Research Signpost. 139150. Grpin, C., Dagnino, L., Robitaille, L., Haberstroh, L., Antakly, T., & Nemer, M. (1994). A hormone-encoding gene identifies a pathway for cardiac but not skeletal muscle gene transcription. Mol Cell Biol., 14 (5), 3115-3129. Guo, H. S., Cai, Z. X., Zheng, H. F., Li, X. L., Cui, Y. F., Wang, Z. Y., Xu, W. X., Lee, S. J., & Kim, Y. C. (2003). Role of calciumactivated potassium currents in CNP-induced relaxation of gastric antral circular smooth muscle in guinea pigs. World J Gastroenterol, 9 (9), 2054-2059. Guo, H. S., Cui, X., Cui, Y. G., Kim, S. Z., Cho, K. W., LI, Z. L., & Xu, W. X. (2003). Inhibitory effect of C-type natriuretic peptide on spontaneous contraction in gastri c antral circular smooth muscle of rat. Acta Pharmacol Sin, 10, 1021-1026. Guo, H. S., Jin, Z., Jin, Z. Y., Li, Z. H., Cui, Y. F., Wang, Z. Y., & Xu, W. S. (2003). Comparative study in the effect of C-type natriuretic peptide on gastric motility in various animals. World J Gastroenterol, 9 (3), 547-552.
110 Hama, N., Itoh, H., Shirakami, G., Nakagawa, O., Suga, S., Ogawa, Y., Masuda, I., Nakanishi, K., Yoshimasa, T., & Hashimoto, Y. (1995). Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation, 92 (6), 1558-1564. Hass, G. M., & Taylor, C. B. ( 1948). A quantitative hypothermal method for the production of local injury to tissue. Arch. Pathol., 45 563. He, P., Zeng, M., & Curry, F. E. (1998). cGMP modulates basal and activated microvessel permeability independently of [Ca2+]i. Am J Physiol, 274 ((6pt2)), H1865-1874. Hecht, G., Pestic, L., Nikcevic, G ., Koutsouris, A., Tripuraneni, J., Lorimer, D. D., Nowak, G., Gue rriero, V., Jr.,, Elson, E. L., & Lanerolle, P. D. (1996). Expression of the catalytic domain of myosin light chain kinase incr eases paracellular permeability. Am J Physiol. 1996 Nov;271(5 Pt 1):C1678-84., 271 ((5 pt 1)), C1678-1684. Henry, J. P., & Pearce, J. W. (1956). The possible role of cardiac atrial stretch receptors in the induct ion of changes in urine flow. J Physiol, 131 (3), 572-585. Hirokawa, N., & Heuser, J. E. (1981). Quick-freeze, deep-etch visualization of the cytoskeleton beneath surface differentiations of intestinal epithelial cells. J Cell Biol, 91 (2 Pt 1) (399-409). Hlschermann, H., Noll, T., Hempel, A., & Piper, H. M. (1997). Dual role of cGMP in modulation of macromolecule permeability of aortic endothelial cells. Am J Physiol, 272((1pt2)), H91-98. Huwer, H., Nikoloudakis, N., Rissland, J., Vollmar, B., Menger, M. D., & Schfers, H. J. (1998). In vivo analysis of microvascular injury after myocardial cryothermia. J Surg Res, 79 (1), 1-7.
111 Huxley, V. H., Tucker, V. L., Verbur g, K. M., & Freeman, R. H. (1987). Increased capillary hydraulic cond uctivity induced by atrial natriuretic peptide. Circ Res., 60(2), 304-307. Itoh, H., Nakao, K., Yamada, T., Shirakami, G., Kangawa, K., Minamino, N., Matsuo, H., & Imur a, H. (1988). Antidipsogenic action of a novel peptide, 'brain natriuretic peptide', in rats. Eur J Pharmacol., 150 (1-2), 193-196. Iwata, T., Uchida-Mizuno, K., Katafu chi, T., Ito, T., Hagiwara, H., & Hirose, S. (1991). Bifunctional atrial natriuretic peptide receptor (type A) exists as a disulfid e-linked tetramer in plasma membranes of bovine adrenal cortex. J Biochem., 110 (1), 35-39. James, K. B., Troughton, R. W., Fe ldschuh, J., Soltis, D., Thomas, D., & Fouad-Tarazi, F. (2005). Blood volume and brain natriuretic peptide in congestive heart failure: a pilot study. Am Heart J, 150 (5), 984. Jamieson, J. D., & Palade, G. E. (1964). Specific granules in atrial muscle cells. The Journal of Cell Biology, 23 151-172. Januszewicz, P., Thibault, G., Gutkow ska, J., Garcia, R., Mercure, C., Jolicoeur, F., Genest, J., & M., C. (1986). Atrial natriuretic factor and vasopressin during dehydrat ion and rehydration in rats. Am J Physiol, 251 (4 Pt 1), E497-501. John, S. W., Krege, J. H., Oliver, P. M., Hagaman, J. R., Hodgin, J. B., Pang, S. C., Flynn, T. G., & Smithies, O. (1995). Genetic decreases in atrial natriureti c peptide and salt-sensitive hypertension. Science., 267 (5198), 679-681. Johns, D. G., Ao, Z., Heidrich, B. J., Hunsberger, G. E., Graham, T., Payne, L., Elshourbagy, N., Lu, Q ., Aiyar, N., & Douglas, S. A. (2007). Dendroaspis natriuretic peptide binds to the natriuretic peptide clearance receptor. Biochem Biophys Res Commun.
112 Kambayashi, Y., Nakao, K., Kimura, H., Kawabata, T., Nakamura, M., Inouye, K., Yoshida, N., & Im ura, H. (1990). Biological characterization of human brain natriuretic peptide (BNP) and rat BNP: species-specific actions of BNP. Biochem Biophys Res Commun., 173 (2), 599-605. Kangawa, K., Tawaragi, Y., Oikawa, S., Mizuno, A., Sakuragawa, Y., Nakazato, H., Fukuda, A., Mina mino, N., & Matsuo, H. (1984). Identification of rat gamma atrial natriuretic polypeptide and characterization of the cDNA encoding its precursor. Nature. Nov 8-14;312(5990):152-5.Links, 312 (5990), 152-155. Katafuchi, T., Takashima, A., Kashiw agi, M., Hagiwara, H., Takei, Y., & S., H. (1994). Cloning and expressi on of eel natriuretic-peptide receptor B and comparison wi th its mammalian counterparts. Eur J Biochem., 222 (3), 835-842. Keller, T. C., & Mooseker, M. S. (1982). Ca++-calmodulin-dependent phosphorylation of myosin, an d its role in brush border contraction in vitro. J Cell Biol, 95 (3), 943-959. Kelley, C. A., & Adelstein, R. S. (1990). The 204-kDa smooth muscle myosin heavy chain is phosphorylated in intact cells by casein kinase II on a serine near the carboxyl terminus. J Biol Chem, 265 (29), 17876-17882. Kelly, R. B. (1985). Pathways of protein secretion in eukaryotes. Science, 230 (4721), 25-32. Kiemer, A. K., Weber, N. C., Frst, R., Bildner, N., Kulhanek-Heinze, S., & Vollmar, A. M. (2002). Inhibition of p38 MAPK activation via induction of MKP-1: atrial natriuretic peptide reduces TNFalpha-induced actin polymerization and endothelial permeability. Circ Res., 90 (8), 874-881. Kinnunen, P., Vuolteenaho, O., Uusi maa, P., & Ruskoaho, H. (1992). Passive mechanical stretch releases atrial natriuretic peptide from rat ventricular myocardium. Circ Res., 70 (6), 1244-1253.
113 Kisch, B. (1956). Electron microscopy of the atrium of the heart. I. Guinea pig. Exp Med Surg., 14 (2-3), 99-112. Klinger, J. R., Warburton, R., Cari no, G. P., Murray, J., Murphy, C., Napier, M., & Harrington, E. O. (2006). Natriuretic peptides differentially attenuate thrombin-induced barrier dysfunction in pulmonary microvascular endothelial cells. Exp Cell Res, 312 (4), 401-410. Komatsu, Y., Nakao, K., Itoh, H., Suga, S., Ogawa, Y., & Imura, H. (1992). Vascular natriuretic peptide. Lancet., 340 (8819), 622. Krack, A., Sharma, R., Figulla, H. R., & Anker, S. D. (2005). The importance of the gastrointestinal system in the pathogenesis of heart failure. 2368-74, 2005. Eur Heart J, 26 (22), 2368-2374. Kubes, P. (1993). Nitric oxide-in duced microvascular permeability alterations: a regulatory role for cGMP. Am J Physiol, 265 ((6pt2)), H1909-1915. Kuhn, M. (2005). Cardiac and intestin al natriuretic peptides: sights from genetically modified mice. Peptides., 26 (6), 1078-1085. Lang, R. E., Thlken, H., Ganten, D., Luft, F. C., Ruskoaho, H., & Unger, T. (1985). Atrial natriure tic factor--a circulating hormone stimulated by volume loading. Nature, 314 (6008), 264-266. Lee, M. E., Miller, W. L., Edwards, B. S., & Burnett, J. C., Jr. (1989). Role of endogenous atrial natriuretic factor in acute congestive heart failure. J Clin Invest, 84 (6), 1962-1966. Levin, E. R., Weber, M. A., & Mills, S. (1988). Atrial natriuretic factorinduced vasodepression occurs through central nervous system. Am J Physiol, 255 (3 Pt 2), H616-622.
114 Lewicki, J. A., Greenberg, B., Yamanaka, M., Vlasuk, G., Brewer, M., Gardner, D., Baxter, J., Johnson, L. K., & Fiddes, J. C. (1986). Cloning, sequence analysis, and processing of the rat and human atrial natriuretic peptide precursors. Fed Proc., 45 (7), 20862090. Li, C. H., Pan, L. H., Li, C. Y., Zhu, C. L., & Xu, W. X. (2006). Localization of ANP-synthesizing cells in rat stomach. World J Gastroenterol, 12(35), 5674-5679. Li, X., & Gorodeski, G. (2006). Non-muscle myosin-II-B filament regulation of paracellular resistan ce in cervical epithelial cells is associated with modulation of the cortical acto-myosin. J Soc Gynecol Investig, 13 (8), 579-591. Li, Y., Kishimoto, I., Saito, Y., Ha rada, M., Kuwahara, K., Izumi, T., Takahashi, N., Kawakami, R., Tanimoto, K., Nakagawa, Y., Nakanishi, M., Adachi, Y., Garbers, D. L., Fukamizu, A., & Nakao, K. (2002). Guanylyl cyclase-A inhibits angiotensin II type 1A receptor-mediated cardiac remodelin g, an endogenous protective mechanism in the heart. Circulation, 106 (13), 1722-1728. Li, Y. Y., McTiernan, C. F., & Fe ldman, A. M. (2000). Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res, 46(2), 214-224. Li, Z., ,, & Goy, M. F. (1993). Peptide-regulated guanylate cyclase pathways in rat colon: in situ localization of GCA, GCC, and guanylin mRNA. Am J Physiol, 265 (2 pt 1), G394-402. Linask, K. K., & Tsuda, T. (2000). A pplication of plastic embedding for sectioning whole-mount immunostained early vertebrate embryos. Methods Mol Biol., 135 165-173. Lofton, C. E., Newman, W. H., & Currie M. G. (1990). Atrial natriuretic peptide regulation of endothelia l permeability is mediated by cGMP. Biochem Biophys Res Commun, 172 (2), 793-799.
115 Lohmeier, T. E., Mizelle, H. L., & Reinhart, G. A. (1995). Role of atrial natriuretic peptide in long-term volume homeostasis. Clin Exp Pharmacol Physiol, 22 (1), 55-61. Lopez, M. J., Wong, S. K., Kishimoto, I., Dubois, S., Mach, V., Friesen, J., Garbers, D. L., & Beuve, A. (1995). Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature, 378 (6552), 65-68. Lowe, D. G., Chang, M. S., Hellmiss, R., Chen, E., Singh, S., Garbers, D. L., & Goeddel, D. V. (1989). Human atrial natriuretic peptide receptor defines a new paradigm for second messenger signal transduction. EMBO J. 1989, 8 (5), 1377-1384. Ma, T. Y., Tran, D., Hoa, N., Nguye n, D., Merryfield, M., & Tarnawski, A. (2000). Mechanism of extrace llular calcium regulation of intestinal epithelial tight junc tion permeability: role of cytoskeletal involvement. Microsc Res Tech, 51 (2), 156-168. Madara, J. L., Moore, R., & Carlson, S. L. (1987). Alteration of intestinal tight junction structure and permeability by cytoskeletal contraction. Am J Physiol, 253 ((6 Pt 1)), C854-861. Maisel, A., & Mehra, M. R. (2005). Understanding B-type natriuretic peptide and its role in diagnosing and monitoring congestive heart failure. Clin Cornerstone., 1 (S), 7-17. Malagelada, J. R., & Stanghellini, V. (1985). Manometric evaluation of functional upper gut symptoms. Gastroenterology, 88 (5 Pt 1), 1223-1231. Marie, J. P., Guillemot, H., & Hatt, P. Y. (1976). Degree of granularity of the atrial cardiocytes. Morphometric study in rats subjected to different types of water and sodium load[Article in French]. Pathol Biol (Paris). 24 (8), 549-554.
116 Matsukawa, N., Grzesik, W. J., Takaha shi, N., Pandey, K. N., Pang, S., Yamauchi, M., & Smithies, O. (1999). The natriuretic peptide clearance receptor locally modula tes the physiological effects of the natriuretic peptide system. Proc Natl Acad Sci U S A., 96 (13), 7403-7408. Matsushita, K., Nishida, Y., Hosomi, H., & Tanaka, S. (1991). Effects of atrial natriuretic peptide on wa ter and NaCl absorption across the intestine. Am J Physiol., 260 (R), 6-12. Mearin, F., & Malagelada, J. R. (1993). Gastrointestinal manometry: a practical tool or a research technique? J Clin Gastroenterol, 16 (4), 281-291. Metcalf, W. (1944). The fate and effect s of transfused serum or plasma in normal dogs. J Clin Invest, 23 (3), 403-415. Misono, K. S., Fukumi, H., Grammer, R. T., & Inagami, T. (1984). Rat atrial natriuretic factor: complete amino acid sequence and disulfide linkage essential for biological activity. Biochem Biophys Res Commun, 119 (2), 524-529. Mooseker, M. S. (1976). Brush border motility. Microvillar contraction in triton-treated brush borders isolated from intestinal epithelium. J Cell Biol, 71 (2), 417-433. Mooseker, M. S., Keller, T. C., III .,, & Hirokawa, N. (1983). Regulation of cytoskeletal structure and contractility in the brush border. Ciba Found Symp, 95 (195-215). Morita, H., Hagiike, M., Horiba, T., Miyake, K., Ohyama, H., Yamanouchi, H., Hosomi, H., Kangawa, K., Minamino N., & Matsuo, H. (1992). Effects of br ain natriuretic peptide and Ctype natriuretic peptide infusi on on urine flow and jejunal absorption in anesthetized dogs. Jpn J Physiol, 42 (2), 349-353.
117 Munagala, V. K., Burnett, J. C., Jr., & Redfield, M. M. (2004). The natriuretic peptides in cardiovascular medicine. Curr Probl Cardiol, 29 (12), 707-769. Murakami, N., Elzinga, M., Singh, S. S., & Chauhan, V. P. (1994). Direct binding of myosin II to phospholipid vesicles via tail regions and phosphorylation of the heavy chains by protein kinase C. J Biol Chem, 269 (23), 16082-16090. Nagase, M., Katafuchi, T., Hirose S., & Fujita, T. (1997). Tissue distribution and localization of natriuretic peptide receptor subtypes in stroke-prone spontaneously hypertensive rats. J Hypertens., 15 (11), 1235-1243. Nakagawa, O., Itoh, H., Harada, M ., Komatsu, Y., Yoshimasa, T., & Nakao, K. (1995). Gene regulation of brain natriuretic peptide in cardiocyte hypertrophy by alpha1-adrenergic stimulation. Clin Exp Pharmacol Physiol Suppl., 22 (1), 183-185. Nakanishi, M., Saito, Y., Kishimoto, I., Harada, M., Kuwahara, K., Takahashi, N., Kawakami, R., Nakagawa, Y., Tanimoto, K., Yasuno, S., Usami, S., Li, Y., Adachi, Y., Fukamizu, A., Garbers, D. L., & Nakao, K. (2005). Role of natriuretic peptide receptor guanylyl cyclase-A in myocardial infarction evaluated using genetically engineered mice. Hypertension, 46 (2), 441-447. Nakao, K., Mukoyama, M., Hosoda, K., Suga, S., Ogawa, Y., Saito, Y., Shirakami, G., Arai, H., Jougasaki, M., & Imura, H. (1991). Biosynthesis, secretion, and rece ptor selectivity of human brain natriuretic peptide. Can J Physiol Pharmacol, 69(10), 1500-1506. Nguyen, T. T., Babinski, K., Ong, H ., & De Lean, A. (1990). Differential regulation of natriuretic peptide biosynthesis in bovine adrenal chromaffin cells. Peptides, 11 (5), 973-978.
118 Nguyen, T. T., Lazure, C., Babinski K., Chretien, M., Ong, H., & De Lean, A. (1989). Aldosterone secret ion inhibitory factor: a novel neuropeptide in bovine chromaffin cells. Endocrinology, 124(3), 1591-1593. Ogawa, Y., Nakao, K., Mukoyama, M., Hosoda, K., Shirakami, G., Arai, H., Saito, Y., Suga, S., Jougasaki, M., & Imura, H. (1991). Natriuretic peptides as cardiac hormones in normotensive and spontaneously hypertensive rats. Th e ventricle is a major site of synthesis and secretion of brain natriuretic peptide. Circ Res., 69 (2), 491-500. Ogawa, Y., Nakao, K., Mukoyama, M ., Shirakami, G., Itoh, H., Hosoda, K., Saito, Y., Arai, H., Suga, S., & Jougasaki, M. (1990). Rat brain natriuretic peptide--tissue distribution and molecular form. Endocrinology., 126 (4), 2225-2227. O'Grady, S. M., Field, M., Nash, N. T., & Rao, M. C. (1985). Atrial natriuretic factor inhibits Na-K-Cl cotransport in teleost intestine. Am J Physiol, 249 (5 Pt 1), C531-534. Ohyama, Y., Miyamoto, K., Saito, Y., Minamino, N., Kangawa, K., & Matsuo, H. (1992). Cloning and characterization of two forms of C-type natriuretic peptide receptor in rat brain. Biochem Biophys Res Commun., 183 (2), 743-749. Oikawa, S., Imai, M., Inuzuka, C., Tawaragi, Y., Nakazato, H., & Matsuo, H. (1985). Structure of dog and rabbit precursors of atrial natriuretic polypeptides deduced from nucleotide sequence of cloned cDNA. Biochem Biophys Res Commun., 132 (3), 892899. Olsson, C., & Holmgren, S. (2001) The control of gut motility. Comp Biochem Physiol A Mol Integr Physiol, 128 (3), 481-503. Pacha, J. (2000). Development of intestinal Transport function in Mammals. Physiological Rev., 80 1633-1667.
119 Palade, G. E. (1961). Secretory granules in the atrial myocardium. Anat. Rec., 139 262. Pasini, G. F., Melchioretti, R., Mora A., Buizza, M. A., Almici, C. A., Davoli, C., Pasini, M., & Alberti, P. (1989). Dyspeptic syndrome in heart diseases. G Clin Med, 70 (2), 101-104. Pedram, A., Razandi, M., & Levin, E. R. (2002). Deciphering vascular endothelial cell growth factor/v ascular permeability factor signaling to vascular permeability I nhibition by atrial natriuretic peptide. J Biol Chem, 277 (46), 44385-44398. Pettersson, A., & Johnsson, C. O. ( 1989). Effects of Atrial Natriuretic Peptide (ANP) on jejunal net fluid absorption in the rat. Acta Physiol Scand, 136 (3), 419-426. Pfeifer, A., Aszdi, A., Seidler, U., Ruth, P., Hofmann, F., & Fssler, R. (1996). Intestinal secretory defect s and dwarfism in mice lacking cGMP-dependent protein kinase II. Science., 274 (5295), 20822086. Potter, L. R. (2005). Domain an alysis of human transmembrane guanylyl cyclase receptors: implications for regulation. Front Biosci, 10 1205-1220. Potter, L. R., & Garbers, D. L. (1992). Dephosphorylation of the guanylyl cyclase-A receptor causes desensitization. J Biol Chem, 267 (21), 14531-14534. Potter, L. R., & Hunter, T. (1998) Phosphorylation of the kinase homology domain is essential for activation of the A-type natriuretic peptide receptor. Mol Cell Biol, 18 (4), 264-272. Rademaker, M. T., Cameron, V. A., Charles, C. J., Espiner, E. A., Nicholls, M. G., Pemberton, C. J., & Richards, A. M. (2000). Neurohormones in an ovine model of compensated postinfarction left ventricular dysfunction. Am J Physiol Heart Circ Physiol, 278 (3), H731-740.
120 Richet, G., & Hornych, A. (1969). The effect of an expansion of extracellular fluids on net Na fl ux in the jejunum of rats. An experimental model for the study of the third factor. Nephron, 6 (3), 365-378. Rodewald, R., Newman, S. B., & Karn ovsky, M. J. (1976). Contraction of isolated brush borders from the intestinal epithelium. J Cell Biol, 70 (3), 541-554. Roell, W., Lu, Z. J., Bloch, W., Siedner, S., Tiemann, K., Xia, Y., Stoecker, E., Fleischmann, M., Bo hlen, H., Stehle, R., Kolossov, E., Brem, G., Addicks, K., Pfitzer, G., Welz, A., Hescheler, J., & Fleischmann, B. K. (2002). Cellu lar cardiomyoplasty improves survival after myocardial injury. Circulation, 105(20), 24352441. Rose, R. A., & Giles, W. R. (2007). Natriuretic peptide C receptor (NPR-C) signaling in the heart and vasculature. J Physiol., Epub ahead of print Rostgaard, J., & Thuneberg, L. (1972). Electron microscopical observations on the brush border of proximal tubule cells of mammalian kidney. Z Zellforsch Mikrosk Anat, 132 (4), 473-496. Ruskoaho, H. (1992). Atrial natriureti c peptide: synthesis, release, and metabolism. Pharmacol Rev, 44 (4), 479-602. Rybalkin, S. D., Yan, C., Bornfeldt, K. E., & Beavo, J. A. (2003). Cyclic GMP phosphodiesterases and re gulation of smooth muscle function. Circ Res., 93 (4), 280-291. Saito, Y., Nakao, K., Itoh, H., Ya mada, T., Mukoyama, M., Arai, H., Hosoda, K., Shirakami, G., Su ga, S., & Minamino, N. (1989). Brain natriuretic peptide is a novel cardiac hormone. Biochem Biophys Res Commu, 158 (2), 360-368.
121 Santos-Neto, M. S., Carvalho, A. F., Monteiro, H. S., Forte, L. R., & Fonteles, M. C. (2006). Interactio n of atrial natriuretic peptide, urodilatin, guanylin and uroguanylin in the isolated perfused rat kidney. Regul Pept, 136 (1-3), 14-22. Sato, F., Kamoi, K., Wakiya, Y., Ozaw a, T., Arai, O., Ishibashi, M., & Yamaji, T. (1986). Relationship be tween plasma atrial natriuretic peptide levels and atrial pressure in man. J Clin Endocrinol Metab, 63(4). Schirger, J. A., Heublein, D. M., Ch en, H. H., Lisy, O., Jougasaki, M., Wennberg, P. W., & Burnett, J. C., Jr.,. (1999). Presence of Dendroaspis natriuretic peptide-like immunoreactivity in human plasma and its increase during human heart failure. Mayo Clin Proc, 74 (2), 126-130. Schulz, S., Wedel, B. J., Matthews, A., & Garbers, D. L. (1998). The cloning and expression of a new guanylyl cyclase orphan receptor. J Biol Chem, 273 (2), 1032-1037. Scotland, R. S., Ahluwalia, A., & Hobbs, A. J. (2005). C-type natriuretic peptide in vascula r physiology and disease. Pharmacol Ther, 105 (2), 85-93. Scott, R. B., & Maric, M. (1991). The Effect of Atrial Natriuretic Peptide on Small intestinal co ntractility and Transit. Peptides, 12 799803. Seidman, C. E., Bloch, K. D., Klein, K. A., Smith, J. A., & Seidman, J. G. (1984). Nucleotide sequences of the human and mouse atrial natriuretic factor genes. Science, 226 (4679), 1206-1209. Seilhamer, J. J., Arfsten, A., Miller, J. A., Lundquist, P., Scarborough, R. M., Lewicki, J. A., & Porter, J. G. (1989). Human and canine gene homologs of porcine brain natriuretic peptide. Biochem Biophys Res Commun., 165 (2), 650-658.
122 Sellers, J. R. (2000). Myosins: a diverse superfamily. Biochim Biophys Acta., 1496 (1), 3-22. Shamsham, F., & Mitchell, J. (2000). Essentials of the diagnosis of heart failure. Am Fam Physician, 61 (5), 1319-1328. Sharkey, K., Gall, D., & MacNaugh ton, W. (1991). Distribution and function of brain natriuretic peptide in the stomach and small intestine of the rat. Regul Pept., 34 (1), 61-70. Silver, M. A. (2006). The natriuretic peptide system: kidney and cardiovascular effects. Curr Opin Nephrol Hypertens, 15 (1), 1421. Sjvall, H., Abrahamsson, H., Westla nder, G., Gillberg, R., Redfors, S., Jodal, M., & Lundgren, O. (1986). Intestinal fluid and electrolyte transport in man during reduced circulating blood volume. Gut, 27 (8), 913-918. Sleight, P. (1981). Cardiac vomiting. Br Heart J, 46 (1), 5-7. Smolenski, A., Burkhardt, A. M., Eige nthaler, M., Butt, E., Gambaryan, S., Lohmann, S. M., & Walter, U. (1998). Functional analysis of cGMP-dependent protein kinases I and II as mediators of NO/cGMP effects. Naunyn Schmiedebergs Arch Pharmacol. 1998 Jul;358(1):134-9. Links., 358 (1), 134-139. Spinale, F. G. (2002). Matrix Metalloproteinases Regulation and Dysregulation in the Failing Heart. Circulation Research. 2002;90:520-530, 90 (5), 520-530. Stingo, A. J., Clavell, A. L., Heublein, D. M., Wei, C. M., Pittelkow, M. R., & Burnett, J. J. (1992). Presen ce of C-type natriuretic peptide in cultured human endothelial cells and plasma. Am J Physiol., 263 (4 pt 2), H1318-1321.
123 Strauss, M. B., Davis, R. K., Rosenbaum, J. D., & Rossmeisl, E. C. (1951). Water diuresis produced during recumbency by the intravenous infusion of isotonic saline solution. J Clin Invest, 30 (8), 862-868. Sudoh, T., Kangawa, K., Minamino, N., & Matsuo, H. (1988). A new natriuretic peptide in porcine brain. Nature, 332 (6159), 78-81. Sudoh, T., Minamino, N., Kangawa, K., & Matsuo, H. (1990). C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun, 168 (2). Suzuki, R., Takahashi, A., Hazon, N ., & Takei, Y. (1991). Isolation of high-molecular-weight C-type natriuretic peptide from the heart of a cartilaginous fish (European dogfish, Scyliorhinus canicula). FEBS Lett., 282 (2), 321-325. Swanljung-Collins, H., & Collins, J. H. (1991). Ca2+ stimulates the Mg2(+)-ATPase activity of brush border myosin I with three or four calmodulin light chains bu t inhibits with less than two bound. J Biol Chem, 266 (2), 1312-1319. Swanljung-Collins, H., & Collins, J. H. (1992). Phosphorylation of brush border myosin I by protein kinase C is regulated by Ca(2+)stimulated binding of myosin I to phosphatidylserine concerted with calmodulin dissociation. J Biol Chem, 267 (5), 3445-3454. Tamaoki, J., Tagaya, E., Nishimura, K., Isono, K., & Nagai, A. (1997). Role of Na(+)-K+ ATPase in cyclic GMP-mediated relaxation of canine pulmonary artery smooth muscle cells. Br J Pharmacol, 122 (1), 112-116. Thorball, N. (1981). FITC-dextran tracers in microcirculatory and permeability studies using co mbined fluorescence stereo microscopy, fluorescence light microscopy and electron microscopy. Histochemistry, 71 (2), 209-233.
124 Thorn, P. N., Donald, D., E., & Shepherd, J. T. (1976). Role of heart and lung receptors with nonm edullated vagal afferents in circulatory control. Circ Res, 38 (6 suppl 2), 2-9. Thuerauf, D. J., Hanford, D. S., & Glembotski, C. C. (1994). Regulation of rat brain natriuretic peptide tr anscription. A potential role for GATA-related transcription fact ors in myocardial cell gene expression. J Biol Chem, 269 (27), 17772-17775. Tokola, H., Hautala, N., Marttila, M., Magga, J., Pikkarainen, S., Kerkel, R., Vuolteenaho, O., & Ruskoaho, H. (2001). Mechanical load-induced alterations in B-type natriuretic peptide gene expression. Can J Physiol Pharmacol, 79 (8), 646-653. Totsune, K., Takahashi, K., Ohneda M., Itoi, K., Murakami, O., & Mouri, T. (1994). C-type natriuretic peptide in the human central nervous system: distribution and molecular form. Peptides, 15 (1), 37-40. Tsukada, T., Rankin, J. C., & Takei, Y. (2005). Involvement of drinking and intestinal sodium absorption in hyponatremic effect of atrial natriuretic peptide in seawater eels. Zoolog Sci., 22 (1), 77-85. Turner, J. R., Rill, B. K., Carlson, S. L., Carnes, D., Kerner, R., Mrsny, R. J., & Madara, J. L. (1997). Physiological regulation of epithelial tight junctions is asso ciated with myosin light-chain phosphorylation. Am J Physiol, 273((4pt1)), C1378-1385. van den Bos, E. J., Mees, B. M., de Waard, M. C., de Crom, R., & Duncker, D. J. (2005). A novel model of cryoinjury-induced myocardial infarction in the mous e: a comparison with coronary artery ligation. Am J Physiol Heart Circ Physiol, 289(3), H12911300.
125 Vellaichamy, E., Zhao, D., Somanna, N., & Pandey, K. N. (2007). Genetic disruption of guanylyl cyclase/natriuretic peptide receptor-A upregulates ACE and AT1 receptor gene expression and signaling: role in cardiac hypertrophy. Physiol Genomics, 31 (2), 193-202. Veress, A. T., & Sonnenberg, H. (1984). Right atrial appendectomy reduces the renal response to acute hypervolemia in the rat. Am J Physiol, 247 (3 Pt 2), R610-613. Vesely, D. L., Dietz, J. R., Parks, J. R., Antwi, E. A., Overton, R. M., McCormick, M. T., Cintron, G., & Schocken, D. D. (1999). Comparison of vessel dilator an d long-acting natriuretic peptide in the treatment of congestive heart failure. Am Heart J, 138 (4Pt1), 597-598. Villarreal, D., Freeman, R. H., Davis, J. O., Verburg, K. M., & Vari, R. C. (1986). Effects of atrial appendectomy on circulating atrial natriuretic factor during vo lume expansion in the rat. Proc Soc Exp Biol Med, 183 (1), 54-58. Vlasuk, G. P., Miller, J., Bencen, G. H., & Lewicki, J. A. (1986). Structure and analysis of the bo vine atrial natriuretic peptide precursor gene. Biochem Biophys Res Commun., 136 (1), 396403. Vollmar, A. M. (1990). Atrial natriuretic peptide in peripheral organs other than the heart. Klin Wochenschr, 68 (14), 699-708. Vuolteenaho, O., Arjamaa, O., & Li ng, N. (1985). Atrial natriuretic polypeptides (ANP): rat atria store high molecular weight precursor but secrete processed peptides of 25-35 amino acids. Biochem Biophys Res Commun, 129 (1), 82-88. Weber, N. C., Blumenthal, S. B., Hartung, T., Vollmar, A. M., & Kiemer, A. K. (2003). ANP inhibits TNF-alpha-induced endothelial MCP-1 expression--involvement of p38 MAPK and MKP-1. J Leukoc Biol, 74 (5), 932-941.
126 Wei J. Y. (1988). Nausea and vo miting during acute myocardial infarction. Am J Cardiol., 62 (1), 178. Welt, L. G., & Orloff, J. (1951). The effects of an increase in plasma volume on the metabolism and excretion of water and electrolytes by normal subjects. J Clin Invest, 30 (7), 751-761. Westendorp, R. G., Draijer, R., Meinders, A. E., & van Hinsbergh, V. W. (1994). Cyclic-GMP-mediated decrease in permeability of human umbilical and pulmonary artery endothelial cell monolayers. J Vasc Res, 31(1), 42-51. Wu, C., Wu, F., Pan, J., Morser, J., & Wu, Q. (2003). Furin-mediated processing of Pro-C-type natriuretic peptide. J Biol Chem., 278 (28), 25847-25852. Yamanaka, M., Greenberg, B., Johnson L., Seilhamer, J., Brewer, M., Friedemann, T., Miller, J., Atlas, S., Laragh, J., & Lewicki, J. (1984). Cloning and sequence anal ysis of the cDNA for the rat atrial natriuretic factor precursor. Nature. Nov 814;312(5990):152-5.Links, 309 (5970), 719-722. Yandle, T. G. (1994). Biochemi stry of natriuretic peptides. J Intern Med, 235(6), 561-576. Yasuda, O., Chijiiwa, Y., Motomura Y., Ochiai, T., & Nawata, H. (2000). Interaction between brain natriuretic peptide and atrial natriuretic peptide in caecal circular smooth muscle cells. Regul Pept., 86 125-132. Yoshihara, A., Kozawa, H., Minamino N., Kangawa, K., & Matsuo, H. (1990). Isolation and sequence de termination of frog C-type natriuretic peptide. Biochem Biophys Res Commun, 173 (2), 591598.
127 Zahraoui, A., Joberty, G., Arpin, M., Fontaine, J. J., Hellio, R., Tavitian, A., & Louvard, D. (1994). A small rab GTPase is distributed in cytoplasmic vesicles in non polarized cells but colocalizes with the tight junction marker ZO-1 in polarized epithelial cells. J Cell Biol, 124 (1-2). Zeidel, M. L. (1993). Hormonal regulation of inner medullary collecting duct sodium transport. Am J Physiol., 265 (2 Pt 2), F159-173. Zhu, B., & Herbert, J. (1996). Centra l antagonism of atrial natriuretic peptides on behavioral and hormonal responses to angiotensin II: mapping with c-fos. Brain Res, 734 (1-2), 55-60.
128 BIBLIOGRAPHY Chang EB and Rao MC (1994). New York. Raven Pr ess Intestinal water and electrolyt e transport: Mechanisms of physiological and adaptive responses in; Johnson LR ed. Physiology of the gastrointetsinal tract. 3 rd edition Clerico A and Emdin M (2006). Natriu retic Peptides-Hormones of the Heart: Springer-Verlag Italia Foster DC, Garbers DL and Wedel BJ (1997). In Sampson WK and Levin ER, Editors (1997). Natriuretic Peptides in Health and Disease: Humana Press, Totowa, NJ Guyton AC, and Hall JE (1996) Textbook of Medical Physiology: W.B.Saunders Company. Jeon KW (2000). Structural and Functional Evolution of the Natriuretic Peptide System in Vertebrates. (In) International Reviews of Cytology: Academic Press Kersti K. Linask and Takeshi Ts uda (2000) Application of plastic embedding for sectioning whol e mount immunostained early vertebrate embryos. (In) Developmental biology protocols: Humana Press Rocky S. Tuan and Cecilia W. Lo (2000). Developmental Biology protocols : Humana Press Sampson WK and Levin ER, Editor s (1997). Natriuretic Peptides in Health and Disease: Humana Press
130 APPENDIX A Abbreviations Used ACE Angiotensin converting enzyme ANF Atrial natriuretic factor ANOVA Analysis of variance ANP Atrial natriuretic peptide AT1 Angiotensin II receptor type 1A BNP B-type natriuretic peptide cANF c-Atrial natriuretic factor (peptide) cGMP Cyclic guanylyl mono phosphate CNP C-type natriuretic peptide DMSO Dimethyl sulfoxide DNP Deandropsis natriuretic peptide FITC Fluorescein-isothiocyanate GC guanylyl cyclase GI Gastrointestinal GTP Guanylyl tri phosphate i.d. Internal diameter i.v. Intravenous
131 i.P. Intraperiotneal KDa Kilo Dalton KHD Kinase homology domain KO Knockout LAD Left anterior descending artery LSD Least square difference LV Left ventricle MAP Mitogen activated pathway MI Myocardial infarction MKP Mitogen activated kinase phosphatase NPR-A Natriuretic peptide receptor type A NPR-B Natriuretic peptide receptor type B NPR-C Natriuretic peptide receptor type C o.d. Outside diameter PBS Phosphate buffered saline PDE Phosphodiesterase PICProbe induction catheter PKG Protein kinase G RFU Relative fluorescence units RIA Radioimmunoassay RV Right ventricle
132 TNF Tumor necrosis factor VEGF Vascular endothelium derived growth factor WT Wild type
ABOUT THE AUTHOR Anteneh Addisu graduated with MD from Addis Ababa University in Ethiopia and completed internal medicine residency at St. Vincent medical center (New York) where he was also chief resident. After six years of private practice in internal medicine, he joined the cardiac peptide lab of Dr. John R. Dietz as a PhD student in 2004 to pursue his interest in molecular workings of the heart. He has won numerous awards including a WHO sponsored visiting scholarship to the Univer sity of Washington, honored as resident of the year and chief resident, elected to fellowship of the American College of Physicians, awarded the national science foundations integrative graduate research education and training scholarship and recently was given the new investigator travel award from the American Heart Association. As part of this dissertation he has authored an original article and several abstracts and has made several presentations at regional and national meetings.